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SUMMARY 
Bindarit is an original compound with peculiar anti-inflammatory activity due to 
a selective inhibition of a subfamily of inflammatory chemokines, including the 
monocyte chemotactic proteins MCP-1/ CCL2, MCP-3/CCL7, and MCP-2/CCL8.  
It is well known that chemokines have a crucial role in initiating and progressing 
neointima formation by controlling each step of the vascular remodelling in response 
to various noxious stimuli. The induction of MCP-1 not only correlates with 
macrophage accumulation but there is strong evidence for an important role of MCP-
1 in vascular smooth muscle cell (SMC) proliferation and migration, processes that 
contribute substantially to neointima formation after arterial stenting and balloon 
angioplasty. 
In this thesis, we investigated the effect of bindarit on neointima formation using 
three animal models of arterial injury: rat carotid artery balloon angioplasty, wire-
induced carotid injury in apolipoprotein E-deficient (apoE
-/-
) mice, and in stent 
stenosis in preclinical porcine coronary stent model. 
Treatment of rats with bindarit (200 mg/kg/day) significantly reduced balloon 
injury-induced neointima formation by 39% at day 14 without affecting re-
endothelialization and reduced the number of medial and neointimal proliferating 
cells at day 7 by 54 and 30%, respectively. These effects were associated with a 
significant reduction of MCP-1 levels both in sera and in injured carotid arteries of 
rats treated with bindarit. In addition, in vitro data showed that bindarit (10–300 μM) 
reduced rat vascular smooth muscle cell (SMC) proliferation, migration, and 
invasion, processes contributing to the injury-induced neointima formation in vivo.  
Similar results were observed in hypercholesterolaemic apoE
-/-
 mice in which 
bindarit administration resulted in a 42% reduction of the number of proliferating 
cells at day 7 after carotid injury and in a 47% inhibition of neointima formation at 
day 28. Analysis of the cellular composition in neointimal lesions of apoE
-/-
 mice 
treated with bindarit showed that the relative content of macrophages and the number 
of SMCs were reduced by 66 and 30%, respectively, compared with the control 
group. 
One or 2 bare metal stents (Multi-Link Vision, 3.5 mm) were deployed (1:1.2 
oversize ratio) in the coronary arteries of 42 pigs (20 bindarit versus 22 controls). 
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Bindarit (50 mg/kg per day) was administered orally from 2 days before stenting 
until the time of euthanasia at 7 and 28 days. Bindarit caused a significant reduction 
in neointimal area (39.4%), neointimal thickness (51%), stenosis area (37%), and 
inflammatory score (40%,) compared with control animals, whereas there was no 
significant difference in the injury score between the 2 groups. Moreover, treatment 
with bindarit significantly reduced the number of proliferating cells (by 45%) and 
monocyte/macrophage content (by 55%) in stented arteries at day 7 and 28, 
respectively. These effects were associated with a significant (P<0.05) reduction of 
MCP-1 plasma levels at day 28. In vitro data showed that bindarit (10–300 μmol/L) 
reduced tumor necrosis factor-α (TNF-α, 50 ng/mL)–induced pig coronary artery 
smooth muscle cell proliferation and inhibited MCP-1 production. 
However, the mechanisms underlying the efficacy of bindarit in controlling 
neointimal formation/restenosis have not been fully elucidated. Therefore, we 
investigated the effect of bindarit on human coronary smooth muscle cells activation, 
drawing attention to the phenotypic modulation process, focusing on contractile 
proteins expression as well as proliferation and migration. 
The expression of contractile proteins was evaluated by western blot analysis on 
cultured human coronary smooth muscle cells stimulated with TNF-α (30 ng/mL) or 
fetal bovine serum (FBS, 5%). Bindarit (100-300 μM) reduced the embryonic form 
of smooth muscle myosin heavy chain (SMemb) while increased smooth muscle α-
actin (α-SMA) and calponin in both TNF-α- and FBS-stimulated cells. These effects 
were associated with the inhibition of human coronary smooth muscle cell 
proliferation/migration and both MCP-1 and MCP-3 production. 
The effect of bindarit on smooth muscle cells phenotypic switching was 
confirmed in vivo in the rat balloon angioplasty model. Bindarit (200 mg/Kg/day) 
significantly reduced the expression of SMemb, while increased α-SMA and 
calponin in rat carotid arteries subjected to endothelial denudation. 
The results provided in this thesis show that bindarit given systemically 
significantly reduced neointimal formation in animal models of arterial injury by 
inhibiting SMC proliferation/migration, and macrophage infiltration; these effects 
correlated with a reduction in MCP-1 synthesis.  
Preclinical studies demonstrated that bindarit has a safe toxicological profile and 
is devoid of immunosuppressive, mutagenic, and carcinogenic effects. Phase I 
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clinical studies demonstrated that bindarit (up to a dose of 1200 mg BID) is well 
tolerated and confirmed the lack of overt toxicity suggested by preclinical studies. 
Results of Phase II clinical studies confirmed the good tolerability profile of bindarit 
and demonstrated, at 600 mg BID, significant effects in kidney disease patients. 
Importantly, a double-blind, randomized, placebo-controlled phase II clinical 
trial, with the aim of investigating the effect of bindarit in human coronary 
restenosis, showed that bindarit induced a significant reduction of in-stent late loss. 
In conclusion, evidence of bindarit efficacy could provide clinicians with useful 
complementary or alternative therapeutic tools. 
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1. INTRODUCTION 
 
Vascular disease constitutes a major cause of death and disability in developed countries 
and will soon become a health threat worldwide. This trend motivates major efforts on 
multiple fronts to fight cardiovascular disease, with the goals of prevention as well as 
improved therapy. One prerequisite for success in this quest is increased understanding of 
the very dynamic environment represented by the vascular wall, where several cell types 
interact and undergo profound phenotypic modulation in development and in diseases. 
The prevalent type of CVDs in western societies is the coronary artery disease, in which 
an artery wall thickens because of the deposition of atherosclerotic plaque triggered by LDL 
accumulation within the artery wall.  
The current procedure that allows the endovascular treatment of occlusive coronary 
artery disease, without the need of bypass surgery, is the percutaneous coronary 
intervention, commonly known as angioplasty. This procedure is executed by attaching a 
small balloon to a catheter. Once inflated on the stenosis, the balloon dilates the artery and 
improves blood flow (balloon angioplasty, Figure 1).  
The most problematic complication of percutaneous coronary intervention is a well 
known process called restenosis, defined as the re-narrowing of the artery after initial 
angioplastic treatment, identifiable by a lumen diameter diagnosis of <50% at follow-up 
(Figure 1).  
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Figure 1 
Mature atherosclerotic plaque before intervention (left). Restenosis after balloon angioplasty 
and stent implantation (right) 
 
1.1 Restenosis 
Restenosis comprises two major processes, intimal hyperplasia and vessel remodelling, 
and was proposed to be the arterial wall’s healing response to mechanical injury. Platelet 
aggregation, inflammatory and immune cell infiltration, release of growth factors, vascular 
smooth muscle cells (SMC) proliferation, collagen deposition and extracellular matrix 
(ECM) remodelling were identified as the major events of this response.   
However, the underlying molecular basis of restenosis remains unclear. Experimental 
observations support a causal correlation between inflammation and experimental restenosis 
(Costa MA and Simon DI 2005).  
Several drugs have been used to prevent restenosis, but only a few have shown any 
promise in either human trials or experimental animal models. Valsartan (Peters S et al., 
2001) and some statins (Walter DH et al., 2000) have been studied without any conclusive 
benefits. Cilostazol, an antiplatelet agent that interferes with SMCs proliferation, has shown 
conflicting results (Tanabe Y et al., 2001). Probucol is the first pharmacological agent 
showing to reduce coronary restenosis after angioplasty and the mechanism of preventing 
restenosis appears to be independent of its lipid-lowering effect (Tardif JC et al., 23). The 
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positive results obtained with probucol suggest that restenosis process is associated with 
oxidative stress. Reactive oxygen species are produced after angioplasty and the generation 
of reactive oxygen species and oxidation of lipids impairs endothelial function. Oxidative 
stress exerts toxic effects on SMCs which leads to the activation of inflammatory reactions 
(Rao GN and Berk BC, 1992). Troglitazone have also been studied with some benefits in a 
small human study (Takagi T et al., 2000).  
The introduction of a metallic spring into the popliteal artery of an experimental animal 
by Charles Dotter signalled the beginning of the stent era. However, the first human stent 
implantation did not occur until 1986, and it was only in 1994 that the US Food and Drug 
Administration (FDA) approved the use of stents following two studies that conclusively 
proved the superiority of stents over balloon angioplasty with regards to their long term 
prognosis (Mitra AK and Agrawal DK, 2006). On average, stents appear to have a 10% 
lower rate of restenosis compared with angioplasty and the favourable results due to stent 
usage have been reported in several studies. Unfortunately, stents have an inherent rate of 
restenosis of 10-60% (Whan Lee C et al., 2008). The risk factors of restenosis include the 
method, lesion location (the left anterior descending artery is found to be less susceptible to 
restenosis), diabetes, residual stenosis, number of stents, the stent length, total occlusion and 
late total occlusion, and bifurcating or ostial lesions (Mitra AK and Agrawal DK., 2006). 
Recent technology has created a method of “coating” stents: using a coronary stent for local 
delivery of drugs combines scaffolding with targeted drug action. Stents coated with any of 
several pharmacotherapeutic agents such as heparin, hirudin, GP IIb/IIIa inhibitors, 
sirolimus, and paclitaxel can be used (Whan Lee C et al., 2008). The initial research and 
clinical trials have been concentrated on sirolimus (rapamycin), a macrolide antibiotic with 
immunosuppressive and anti-mitotic properties (Whan Lee C et al., 2008). Prospective, 
randomized clinical trials have shown that in-stent
 
restenosis is reduced by the use of drug-
eluting stents, as
 
compared with bare-metal stents (Lagerqvist B et al., 2007). On the basis of 
prospective
 
trials involving approximately 4500 patients, the FDA approved the use of drug-
eluting stents (Lagerqvist B et al., 2007).
 
With the increased usage of the stents, there are 
reports of problems, such as late stent malapposition, subacute and late thromboses and 
aneurysm formations due to the toxicity associated with this method of treatment. In 
addition, the long term effects of stents are still unknown. Recent reports suggest that drug-
eluting stents may increase the risk of stent thrombosis relative to bare-metal stents (Yan BP 
et al., 2008).
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1.2 Pathogenesis of restenosis 
Restenosis is a hyperplastic, pathologic reaction involving SMCs migration and 
proliferation, ECM formation and remodelling of the arterial wall leading finally to 
reocclusion of the enlarged artery. Similarly to early, fibrous atheromas, human restenotic 
lesions consist mainly of fibrocellular tissue (Virmani R et al., 1994).  
Within minutes following balloon deflation, the artery undergoes elastic recoil due to 
contraction of the elastic fibers of the inner and external lamina, causing up to a 40% lumen 
loss. A thrombotic response triggered by endothelial denudation, and medial dissection due 
to the mechanical injury of the angioplasty procedure, lead to platelet adherence and 
aggregation on the exposed sub-endothelial surface. Neointimal formation is a complicated 
process involving the recruitment of inflammatory cells to the site of injury, the migration of 
SMCs from the media to the intima, and the proliferation of these cells. Growth factors and 
cytokines are the major stimuli for proliferation of SMCs after the injury (Serruys PW et al., 
1988). The earliest step in the process of in-stent restenosis, before SMCs proliferation, is 
platelet deposition and aggregation (Chandrasekar B et al., 2000). Platelets release multiple 
growth and migratory-promoting factors in addition to those released from injured vascular 
cells and surrounding extracellular matrix such as thrombin, platelet-derived growth factor 
(PDGF), interleukin (IL)-1, insulin-like growth factor-1 (IGF-1), fibroblast growth factor-2 
(FGF-2), vascular endothelial cell growth factor (VEGF), and others (Topol EJ and Serruys 
PW, 1998; Lincoff AM et al., 1994). This complex interplay of growth factors then regulate 
SMCs migration and proliferation through cell surface receptors and intracellular signalling 
molecules inducing early response genes necessary for cells to leave their quiescent state 
and enter the cell cycle (Sherr CJ and Roberts JM, 1999). The dynamic process of SMCs 
migration involves changes in matrix synthesis such as degradation and organization (Galis 
ZS and Khatri JJ, 2002). Matrix metalloproteinases, effectors of extracellular matrix 
degradation are upregulated after injury and the degradation of the extracellular matrix 
allows SMCs to migrate to the intima (Galis ZS and Khatri JJ, 2002). 
Restenosis after balloon angioplasty seems to be determined primarily by the direction 
and magnitude of vessel wall remodeling. In contrast, the major limitation of stent 
implantation is the initiation of neointimal tissue proliferation within and adjacent to the 
stent (Indolfi C. et al., 1999).  
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 1.2.1 Vascular smooth muscle cell activation 
SMC activation is a prominent mechanism of the intimal hyperplasia at the base of the 
restenosis. Normally, vascular SMCs the media reside in a quiescent, differentiated state, 
and express a unique repertoire of contractile proteins to keep vascular tone by contraction 
or relaxation thus being referred to contractile phenotype. However, SMCs maintain 
considerable plasticity (Owens GK et al., 2004). After disruption of the normal steady state 
by vascular injury or disease, SMCs undergo a process often referred to as phenotypic 
modulation/switching characterized by dramatic increases in the rates of proliferation, 
migration, and synthesis of ECM proteins, growth factors and inflammatory mediators, 
along with decreased expression of SMC-specific/-selective marker genes such as smooth 
muscle α-actin (α-SMA), smooth muscle-myosin heavy chain (SM-MHC), SM22α, h1-
calponin, smoothelin, caldesmon, and telokin (Owens GK et al., 2004).  
 
Figure 2 
The differentiation state of SMCs is highly plastic and dependent on integration of multiple 
local environmental cues (Figure adapted from Owens GK et al., 2004). 
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Early markers of SMC activation, such as expression of nuclear oncogenes are 
detectable as soon as 30 minutes after injury (Bauters C et al., 1992) and/or several hours 
after angioplasty, is associated with the early G1 events preceding DNA synthesis in SMCs.  
Although it is still unclear what actually triggers the process of phenotypic modulation in 
vivo, injurious stimuli are known to alter the environment of the vascular wall by affecting 
endothelial function and inducing platelet adhesion and activation, migration of immune 
cells and changes in the ECM. These environmental changes subsequently induce the 
production of growth factors and cytokines by SMCs, which in turn activate 
autocrine/paracrine pathways leading to further phenotypic modulation. For example, in 
atherogenesis, PDGF produced by SMCs and other cell types, was shown to down regulate 
SMC differentiation markers such as α-SMA and SM-MHC (Owens GK et al., 2004); 
matrix degrading proteases produced by macrophages may contribute to the degradation of 
the basement membrane (Galis ZS et al., 1994), and in restenosis, proteases may also derive 
from the injured SMCs present in the lesion (Yoshida T and Owens GK, 2005). This 
activation renders the SMCs responsive to chemoattractants and mitogens resulting in 
subsequent migration and proliferation, both processes contributing to neointimal 
hyperplasia. 
 
 1.2.2 Immune/Inflammatory response 
For several decades immune modulation of neointimal formation after vascular injury 
has been investigated but the complexities involved continue to obscure a clear 
understanding of this process. However, both antigen-specific and nonspecific immune 
responses could occur during restenosis. 
The major detrimental in innate immune responses associated to vascular injury is the 
macrophage infiltration. De-endothelialisation, provoked by balloon dilatation of the arterial 
wall, in fact, allows to a layer of platelets and fibrin to deposit at the injured site (Toutouzas 
K et al., 2004). An interaction between platelets and leukocytes, that involves the platelet P-
selectin and the β2 integrin molecule Mac-1 (CD11b/CD18), promotes a process of 
leukocyte recruitment and infiltration, which is critical to the inflammatory response (Welt 
FGP and Rogers C, 2002). Analysis of human arterial segments also suggests a critical role 
of inflammation during in-stent restenosis. In the initial phase, post-stent implantation, the 
mural thrombus formation is followed by activation and invasion of SMCs, T-lymphocytes 
and macrophages. After this early neointimal formation, extracellular matrix increases; 
growth factors, cytokines and chemokines are released from leukocytes, SMCs and 
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endothelial cells, thus enhancing the migration of leukocytes across the platelet-fibrin layer 
into the tissue and inducing fibroblast proliferation and transformation to myofibroblasts 
(Toutouzas K et al., 2004). Many chemokines such as interleukin (IL)-8, participate in the 
recruitment of monocytes, leukocytes and neutrophils to areas of vascular injury (Welt FGP 
and Rogers C, 2002). Others, like monocyte chemoattractant protein (MCP)-1, are involved 
in the recruitment of monocytes, basophils and T cells (Welt FGP and Rogers C, 2002), as 
well as activation of SMCs (Charo IF and Taubman MB, 2004). Lately a key player in 
fundamental mechanisms, regulating the development of restenosis, as inflammation and 
proliferation, is the ubiquitin–proteasome system of intracellular protein degradation. 
Proteasome, in fact, is required for the activation of the transcription factor “nuclear factor-
κB” (NF-κB) by degrading its inhibitory IκB protein. Once activated, NF-κB induces the 
transcription of a large number of genes codifying for cytokines and chemokines involved in 
inflammatory and immune responces (Hayden MS and Ghosh S, 2008) as well as a variety 
of genes related to cell differentiation, apoptosis, and proliferation (Karin M, 2006). Cell 
apoptosis or necrosis, occurring during injury, may trigger the release of intracellular 
material, including uric acid and heat-shock proteins that can further enhance the immune 
activation (Dimayuga PC et al., 2010).  
The adaptive immune response appears to be more complex. Prior studies suggest that B 
lymphocytes inhibit neointimal formation (Dimayuga PC et al., 2005), likely through the 
production of immunoglobulin. Similarly, experiments based on using T-cell depletion, T-
cell deficiency, or T-cell transfer indicate the inhibitory role of these cells in arterial injury 
(Hansson GK et al., 1991; Remskar M. et al., 2001; Dimayuga PC et al., 2005). It has been 
observed that T lymphocytes also regulate the repair processes of the vasculature to injury 
by inhibiting SMC proliferation (Hansson GK et al., 1991). Although these data suggest a 
protective role of immune cell activation in response to arterial injury, it has been proposed 
that dendritic cells, also present in neointimal lesions, may have the capacity to induce 
autoimmune responses in T cells (Han JW et al., 2008) exacerbating the inflammatory 
response after vascular injury (Fig. 3). Because the role of T lymphocyte is still unknown, 
few studies have been conducted to investigate the effect of drug eluting stent in spite of the 
use of antiproliferative/immunesuppressive drugs. One study showed a significant reduction 
in T lymphocyte infiltration 8 months after DES implantation; another study showed that 
sirolimus DES increased CD8+ central memory T cells (Dimayuga PC et al., 2010).  
It stands to reason that the role of both innate and adaptive immunity in restenosis 
remains still unclear, thus further studies are needed to obtain a more comprehensive view of 
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this growth regulatory network, also to investigate the benefit of current therapy, especially 
DES. 
 
Figure 3 
Immune response to arterial Injury 
 
1.3 Chemokines as therapeutic targets in vascular pathology 
In humans, the chemokines (chemotactic cytokines) system includes 42 ligands grouped 
in four subfamilies (C, CC, CXC, and CX3C) on the basis of the number and position of N-
terminal-conserved cysteine residues (Figure 4). 
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Figure 4 
Classification of the four families of chemokines and their respective receptors (Figure 
adapted from Rostène et al., 2007) 
 
“CXC” chemokines represent one major chemokine family and are characterized by the 
presence of two cysteines, nearest the N-termini, separated by a single amino acid. The 
prototypical member of CXC chemokines is IL-8. The other major chemokine family is 
called “CC” because the two cysteines are adjacent. CC chemokines are RANTES, 
macrophage inflammatory protein-1α (MIP-1α) and MIP-1β and the monocyte chemotactic 
protein (MCP) subfamily including MCP-1, MCP-2, MCP-3, MCP-4 and MCP-5. The third 
family of chemokines is denoted “C” because of the lone cysteine in the N-terminal domain. 
Two chemokines have been described for this group and are called XCL1 (lymphotactin-α) 
and XCL2 (lymphotactin-ß). The last family, the “CX3C” family, has only one known 
member, fractalkine (FK or CX3CL1) that consists of a soluble chemokine domain fused to 
a mucin-like stalk and a transmembrane domain.  
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Chemokines exert their cellular effects by activating seven transmembrane–domain G-
protein–coupled receptors. Different cell types are characterized by different complements 
of chemokine receptors; this determines whether cells respond to a particular chemokine set. 
Chemokine binding to receptor triggers an intracellular signal transduction cascade that 
activates phosphatidylinositol-3 kinase, increases levels of inositol trisphosphate and 
intracellular calcium, activates Rho and mitogen-activated protein kinases. These events 
cause cell responses, including actin re-arrangement, shape change and chemotaxis. 
Chemokine receptors are divided into different families, CXC chemokine receptors, CC 
chemokine receptors, XC chemokine receptors and CX3C chemokine receptors that 
correspond to the four distinct families of chemokines they bind (Figure 4). 
Chemokines and their receptors have a crucial role in initiating and progressing 
neointimal formation by controlling each step of the vascular remodelling in response to 
various noxious stimuli (Schober A, 2008). Chemokines are produced by the major cells of 
the arterial wall, such as endothelial cells, SMCs, adventitial
 
fibroblasts, leukocytes, as well 
as the circulation. They direct the leukocyte trafficking and activate the
 
SMCs during 
vascular pathology (Schober A, 2008). SMCs, in fact, respond to a number of chemokines 
involved in cell proliferation or intracellular calcium mobilization resulting in induction of 
tissue factor (Charo IF and Taubman MB, 2004), a key factor in the pathogenesis of acute 
coronary syndromes. It is well known that MCP-1 direct the monocyte homing (Schober A, 
2008) as well as SMC proliferation and migration (Selzman CH et al., 2002; Massberg S et 
al., 2003). RANTES induces the leukocyte recruitment through different chemokine 
receptors (Schober A, 2008) and fractalkine  induces both inflammation and SMC 
proliferation during neointimal formation (Schober A, 2008). Eotaxin induces
 
migration of 
cultured SMCs (Kodali RB et al., 2004). 
The importance of chemokines in vascular
 
diseases has sparked intense interest in 
developing broad-based
 
inhibitors of chemokine activity as therapeutic agents. Several 
drugs, already in use as a treatment of vascular pathology or its risk factors, are able to 
modify the chemokine expression. For instance, HMG-CoA reductase inhibitors have been 
demonstrated to reduce, in vitro and in vivo, the expression of several markers of vascular 
inflammation, including chemokines (Apostolakis S et al., 2006). Similar findings have been 
demonstrated for angiotensin converting enzyme (ACE) inhibitors, angiotensin II receptor 
blockade and glitazones (Apostolakis S et al., 2006). Thus, some widely used anti-
atherogenic drugs could mediate their beneficial actions partially through inhibition of 
certain chemokine pathways. 
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Directly blocking chemokine activation is now the goal of prevention as well as therapy 
of vascular disease and several preclinical studies are ongoing in this sense. It has been 
demonstrated that intravenous infusion of the myxoma virus M-T7, that inhibits CC and 
other chemokines, markedly reduced intimal hyperplasia
 
in a rabbit model of arterial injury 
(Charo IF and Taubman MB, 2004). The chemokine
 
antagonist MET-RANTES reduced 
neointimal formation in apolipoprotein E-deficient (apoE
-/-
) mice as well as atherosclerotic 
plaque formation in LDLR
-/- 
mice (Charo IF and Taubman MB, 2004). 
Since initiation and development of atherosclerosis and intimal hyperplasia after 
vascular injury are regulated by MCP-1 (Boring L et al., 1998; Egashira K et al., 2002), 
MCP-1/CCR2 pathway is recently receiving increasing attention. It has been observed that 
eliminating the MCP-1 gene or blocking MCP-1 signalling decreases neointimal hyperplasia 
in several animal models of vascular injury (Furukawa Y et al., 1999; Egashira K et al., 
2007). Catheter-based adenovirus-mediated anti-monocyte chemoattractant gene therapy 
attenuates in-stent neointimal formation in monkeys (Nakano K et al., 2007). Up to now the 
possibility to use an oral inhibitor of MCP-1 pathway, has not yet been investigated. In this 
regard, an original indazolic compound, called bindarit, has been identified. Bindarit inhibits 
MCP-1 synthesis and its ability in reducing neointimal formation has been subject of this 
thesis. 
In the context of MCP-1/CCR2 pathway activation during vascular injury, it is 
interesting to note that CCR2
−/− mice have a ≈60% decrease in intimal hyperplasia and 
medial DNA synthesis in response to femoral arterial injury while MCP-1
−/− 
mice show a 
≈30% reduction in intimal hyperplasia, which is not associated with diminished medial 
DNA synthesis (Charo IF and Taubman MB, 2004). These data suggest that MCP-1 and 
CCR2 deficiencies have distinct and separate effects on arterial injury; therefore, it is 
possible that the results obtained with CCR2
−/− 
mice may not be solely mediated by MCP-1 
but also by other chemokines acting on the same receptor. It is known that CCR2 is shared 
with MCP-3 and that this chemokine acts through interaction with not only CCR2 but also 
CCR1 and CCR3, all expressed on vascular SMCs. The role of MCP-3 in vascular 
pathology is not well known. 
Although in the past few years we have witnessed a rapid increase in our understanding 
of the role of chemokines and their receptors in cardiovascular pathologies, all investigators 
agree on the fact that the precise mechanism of the chemokine pathways involved in the 
response of the arterial wall to vascular injury is not fully elucidated. Much more 
information is needed before chemokine-based therapies can be applied in clinical practice. 
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1.4 Bindarit 
Bindarit, or 2-methyl-2-{[1-phenylmethyl)-1H-indazol-3-y1]methoxy} propanoic acid  
is an original indazolic derivative (Fig. 5), synthesized by Angelini (Angelini Research 
Center—ACRAF, Italy), devoid of any immunosuppressive effects and with no activity on 
arachidonic acid metabolism that was shown to have anti-inflammatory activity in a number 
of experimental animal models of both acute and chronic inflammation. These 
pharmacological activities have been associated with its ability to interfere with monocyte 
recruitment in inflamed tissues, which has been ascribed to a selective inhibitory effect on 
the monocyte chemotactic protein (MCP) subfamily of CC inflammatory chemokines, 
including MCP-1/CCL2, MCP-3/ CCL7, and MCP-2/CCL8 (Bhatia M et al., 2005). 
 
Figure 5 
2-methyl-2-{[1-phenylmethyl)-1H-indazol-3-y1]methoxy} propanoic acid (bindarit) 
 
 
Zoja C. et al. (1998) demonstrated that bindarit retards renal disease and prolongs 
survival in NZB/W mice that have a spontaneous autoimmune disease reminiscent of human 
systemic lupus erythematosus. In fact, bindarit delayed the onset of proteinuria and 
significantly protected from renal function impairment. Appearance of anti-DNA antibodies 
was retarded and survival significantly prolonged by bindarit. Bindarit significantly limited 
glomerular hypercellularity, interstitial inflammation and tubular damage. Renal expression 
of monocyte chemoattractant protein (MCP-1) mRNA (Northern blot) markedly increased 
during the progression of nephritis in association with mononuclear cell infiltration. Bindarit 
completely prevented MCP-1 up-regulation. In another series of experiments, bindarit when 
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started at 4.5 months of age in NZB/W mice improved survival in respect to untreated mice 
in a dose-dependent manner. 
Furthermore, Guglielmotti A et al. (2002) demonstrated that bindarit ameliorates rats 
arthritis induced by Freund’s complete adjuvant injection. The course of arthritis was 
monitored by sequential paw volume measurement and by radiologic and histologic 
evaluations. Bindarit possessed therapeutic activity resulting in a significant inhibition of 
paw inflammation. Evidence for a disease-modifying activity was also indicated by 
amelioration of radiologic alterations and by histological evaluation of joints. Additional 
evidence for beneficial effects in osseous inflammation was provided by an in vitro assay in 
which bindarit inhibited the release of MCP-1 from IL-1 stimulated human osteoblast cells. 
Moreover, in a murine model of LPS-induced cytokine production bindarit reduced MCP-1 
and tumor necrosis factor (TNF)-α increase without affecting IL-1 and IL-6 levels. 
In a model of acute pancreatitis induced by caerulein hyperstimulation, Bhatia M et al. 
(2005) demonstrated that prophylactic as well as therapeutic treatment with bindarit 
significantly reduced MCP-1 levels in the pancreas. Also, this treatment significantly 
protected mice against acute pancreatitis as evident by attenuated hyperamylasemia 
neutrophil sequestration in the pancreas (pancreatic MPO activity), and pancreatic acinar 
cell injury/necrosis on histological examination of pancreas sections.  
In human intestinal epithelial cells (HT-29) bindarit concentration-dependently and 
selectively inhibited MCP-1 secretion (as well as mRNA expression) primed by TNF-α/IFN-
γ. These effects were associated with significant inhibition of MCP-1 and myeloperoxidase 
(MPO) activity in colon extracts. Bindarit exhibits a potent bioactivity in reducing leukocyte 
infiltration, down-regulating MCP-1 synthesis, and preventing the development of severe 
colitis in a mice model of TNBS-induced colitis suggesting a potential use of MCP-1 
synthesis blockers in intestinal inflammation in humans (Bathia M et al., 2008). 
Monocyte chemoattractant proteins mediate myocardial microvascular dysfunction in 
swine renovascular hypertension (HTN) that is associated with inflammation as well as 
impaired cardiac microcirculatory function and structure. Lin J et al. (2009), tested the 
hypothesis that MCPs regulate cardiac microvascular function and structure in swine 
renovascular HTN model. Pigs were studied after 10 weeks of normal, renovascular HTN, 
or renovascular HTN+ bindarit as MCPs inhibitor. Left ventricular (LV) function, 
myocardial microvascular permeability, and fractional vascular volume were assessed by 
fast computed tomography before and after adenosine infusion. Myocardial fibrosis, 
inflammation, and microvascular remodeling were determined ex-vivo. HTN upregulated 
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endothelin-1 expression, myocardial inflammation and microvascular wall thickening, 
which were inhibited by bindarit. MCPs partly mediate myocardial inflammation, fibrosis, 
vascular remodeling, and impaired vascular integrity induced by hypertension. Inhibition of 
MCPs could potentially be a therapeutic target in hypertensive cardiomyopathy. 
The molecular mechanisms responsible for the inhibitory effect of bindarit on monocyte 
recruitment are still unclear. Recently, Mora E et al. (2012) demonstrated in both a mouse 
leukaemic monocyte-macrophage cell line and bone marrow-derived macrophages, that the 
inhibitory effect of bindarit is mediated by the downregulation of the classical NF-kB 
pathway, involving a reduction of IkBα and p65 phosphorylation, a reduced activation of 
NFkB dimers and a subsequently reduced nuclear translocation and DNA binding. Bindarit 
showed a specific inhibitory effect on the p65 and p65/p50 induced MCP-1 promoter 
activation, with no effect on other tested activated promoters (IL-12b/p40, IL-6 and IL-
8/KC). The Authors concluded that bindarit acts on a specific subpopulation of NF-kB 
isoforms and selects its targets within the whole NF-kB inflammatory pathway. 
Interestingly, phase II clinical trials have shown that bindarit is well tolerated and 
significantly reduced urinary MCP-1 and albumin excretion in kidney disease (Perico N et 
al., 2008; Guglielmotti A et al., 2009). 
 
1.5 Specific aims 
We evaluated the effect of bindarit on neointimal formation in animal models of vascular 
injury such as rat carotid artery balloon angioplasty, wire-induced carotid injury in 
apolipoprotein E-deficient (apoE¯/¯) mice, and in-stent stenosis in the preclinical porcine 
coronary stent model. In addition, we also investigated the effect of bindarit on human 
coronary vascular SMC activation, drawing attention to the phenotypic modulation process, 
focusing on contractile proteins expression as well as proliferation and migration. 
The results provided in this thesis strongly support the beneficial effects of bindarit on 
the inflammatory/proliferative processes leading to neointima formation. 
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2. METHODS 
 
2.1 In vitro experiments 
2.1.1 Cell culture 
Primary rat or murine vascular SMCs were isolated from the thoracic aorta of male 
Wistar rats or female apoE¯/¯ mice as previously described (Parenti A et al., 2004). Porcine 
vascular SMCs were isolated from coronary arteries of male pigs as previously described 
(Work LM et al., 2001). 
Cells were grown in Dulbecco’s modified Eagle medium (DMEM; Cambrex Bio 
Science) supplemented with L-glutamine, 10% fetal bovine serum (FBS, Lonza), 100 U/mL 
penicillin, and 100 μg/mL streptomycin, in a humidified incubator at 37 °C in 5% CO2, and 
used between passages 3 to 6 for all experiments. Before initiation of assays, to achieve cell 
quiescence, SMCs in exponential growth were switched into DMEM supplemented with 1% 
FBS for 48 hours. 
Human Coronary Artery Smooth Muscle Cells (CASMCs) were purchased from Lonza 
(lot numb: 6F4008 and 16737) (Maddaluno et al., 2012), grown in Smooth Muscle Basal 
Medium (SmBM; Lonza) supplemented with 0.5 mg/mL hEGF, 5 mg/mL insulin, 1 mg/mL 
hFGF, 50 mg/mL gentamicin/amphotericin-B, 5% fetal bovine serum (FBS, Lonza), in a 
humidified incubator at 37 °C in 5% CO2 and used between passages 3 to 8 for all 
experiments. Before initiation of the assays, CASMCs in exponential growth were switched 
into SmBM supplemented with 0.1% FBS in the absence of growth factors for 48 hours. 
 
2.1.2 Proliferation assay 
Cell proliferation was evaluated using the 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium (MTT) assay. 
SMCs were plated on 48 multi-well plastic culture plates at the density of 1.5x10
4
 
cells/well. After the induction of quiescence, rat or murine SMCs were stimulated with 
platelet derived growth factor-BB (PDGF-BB,10 ng/mL, R&D Systems) for 48 hours, 
porcine SMCs were stimulated with human tumor necrosis factor-α (TNF-α, 50 ng/mL, 
R&D Systems) for 72 hours, and CASMCs were stimulated with TNF-α (30 ng/mL, 
Provitro) or FBS (5%) for 48 hours, in the presence or absence of bindarit (10-300 μM).  
0.5 mg/ml of MTT in Phosphate Buffered Saline (PBS) were added and, after 3 hours, a 
solution containing 50% N,N’-dirnethylformamide and 20% SDS (pH 4.8) was used for the 
solubilisation of the formazan dye. Absorbance values at 570 nm were determined the next 
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day with an Enzyme-linked immunosorbent assay (ELISA) assay reader (Bio-Rad), using 
630 nm as the reference wavelength. 
CASMC proliferation was also evaluated as cell duplication by directly counting the cell 
number. Briefly, 1x10
4
 cells were seeded onto 24-well plastic culture plates and allowed to 
adhere overnight. After the induction of quiescence, the cells were stimulated with TNF-α 
(30 ng/mL) or FBS (5%) in presence or absence of bindarit (10–300 μM). After 72 hours, 
medium was removed, cells were fixed with methanol and stained with 4’,6- diamidino-2-
phenylindole (DAPI). Proliferation was evaluated as cell duplication by counting the 
number of cells in 8 random fields of each well at x100 magnification. 
 
2.1.3 Chemotactic Migration and Invasion 
Vascular SMC migration was evaluated using a modified Boyden chamber (Corning 24 
mm Transwell with 8.0 μm pore polycarbonate membrane insert) coated with rat-tail 
collagen I (Sigma-Aldrich). Biocoat Matrigel invasion chambers (with 8.0 μm pore) were 
used according to the manufacturer’s instructions for invasion studies (Becton–Dickinson). 
Briefly, starved SMCs were trypsinized and pre-treated or not with bindarit (10-300 μM) for 
2 hours. 
Rat aortic SMCs were plated in the upper chamber at the density of 5x10
5
 cells in 150 
μL of DMEM 1%, whereas CASMCs were plated in the upper chamber at the density of 
3x10
4
 cells in 500 μL of SMBM 0.1%, with or without bindarit. 
The lower chamber was filled with 600 μL of DMEM 1% or SMBM 0.1% in the 
absence (untreated cells) or presence of PDGF-BB 10 ng/mL or TNF-α (30 ng/mL) 
respectively. 
Rat SMC migration and invasion were evaluated respectively after 6 hours or 48 hours 
and quantified by counting the number of cells in eight randomly chosen fields per insert. 
CASMC migration and invasion were evaluated after 24 hours. Migrated cells were 
fixed and stained with haematoxylin. Cell chemotaxis was quantified by counting the 
number of cells (magnification x200) per insert. 
 
2.1.4 Enzyme-Linked Immunosorbent Assay (ELISA) on SMCs supernatans 
SMCs were plated as above. After the induction of quiescence, rat SMCs were 
stimulated with 10 ng/mL PDGF-BB (6-48 hours), porcine SMCs were stimulated with 50 
ng/mL TNF-α (12-72 hours), CASMCs were stimulated with 30 ng/mL TNF-α (6-48 hours), 
in the presence or absence of bindarit (10-300 μM). 
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Media were collected and centrifuged at 2000g for 15 minutes at 4 °C, and supernatants 
were immediately frozen at -80 °C until use. Supernatants from rat and porcine SMCs were 
used for MCP-1 measurement by ELISA according to the manufacturer’s instructions 
(OptEIATM, Biosciences, and Pig CCL-2 ELISA kit, Bethyl Laboratories, Montgomery, 
TX). Supernatants from CASMCs were used for MCP-1 (OptEIA, BD) or MCP-3 
(Quantikine Human CCL7/ MCP-3 Immunoassay, R&D Systems) measurement by ELISA. 
 
2.1.5 Evaluation of CASMC Morphological Changes 
CASMCs were used after the induction of quiescence in 48-well plastic culture plates at 
the density of 1x10
4
 cells/well. Cells were stimulated with FBS (5%) in presence or absence 
of bindarit (300 μM). After 48 hours cells were photographed at a magnification of ×200 and 
the images were stored in the image analysis system (LAS, Leica). 
  
2.1.6 Measurement of MMP-2 and MMP-8 Activity by Gelatin Zymography 
CASMCs were cultured in 96 multi-well culture plates in 10% FBS medium until 90% 
confluence. After the induction of quiescence, cells were stimulated with TNF-α (30 ng/mL) 
in the presence or absence of bindarit (300 μM). After 24 hours the media were collected, 
clarified by centrifugation and subjected to electrophoresis in 8% SDS-PAGE containing 1 
mg/mL gelatin. After electrophoresis the gels were re-natured by washing with 2.5% Triton 
X-100, to remove SDS, and by incubation for 24 hours at 37 °C in 50 mM Tris buffer 
containing 200 mM NaCl and 20 mM CaCl2, pH 7.4. The gels were stained with 0.5% 
Coomassie brilliant blue R-250 (Sigma) in 10% acetic acid and 45% methanol and destained 
with 10% acetic acid and 45% methanol. Bands of gelatinase activity appeared as 
transparent areas against a blue background. Gelatinase activity was then evaluated by 
quantitative densitometry. 
 
2.1.7 Total Cellular Extracts 
CASMCs were cultured in 24 multi-well plates until 90% confluence. After the 
induction of quiescence, cells were stimulated with TNF-α (30 ng/mL) or FBS (5%) in 
presence or absence of bindarit (100-300 μM). After 48 hours cells were washed two times 
with ice cold PBS and 30 μL/well of lysis buffer (50 mM Tris-HCl, 1% Triton, 1 mM 
Na3VO4, 1 mM EDTA, 0.2 mM PMSF, 25 μg/mL Leupeptin, 10 μg/mL Aprotinin, 10 mM 
NaF, 150 mM NaCl, 10 mM β-glycerophosphate, 5 mM pyrophosphate, H2O) were added. 
Protein concentration was determined by the Bio-Rad protein assay kit (Bio-Rad). 
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2.1.8 Western blot Analysis on CASMCs 
CASMCs lysates (20 μg) were separated by Sodium Dodecyl Sulphate - PolyAcrylamide 
Gel Electrophoresis (SDS-PAGE), transferred onto nitrocellulose membranes (Millipore) 
and probed with a primary antibody against human α-SMA (1:5000, Sigma- Aldrich), 
calponin (1:5000, Sigma-Aldrich) or MYH9/10 (SMemb, 1:2000, Santa Cruz). The 
membranes were washed three times with 0.5% Triton in PBS and incubated with anti-
mouse immunoglobulins coupled to peroxidase (1:1000; DAKO). The immunocomplexes 
were visualised by the enhanced chemiluminescence (ECL) method, results were analyzed 
by ImageJ densitometry software and normalized to β-actin. 
 
2.2. In vivo experiments 
2.2.1 Animals 
Male Wistar rats (250 g, Harlan Laboratories) and 8 weeks-old female apoE¯/¯ mice 
(Charles River) on a 12-hour light/dark cycle with free access to food and water, were 
maintained at the Department of Experimental Pharmacology, University of Naples Federico 
II. All procedures were performed according to Italian ministerial authorization (DL 116/92) 
and European regulations on the protection of animals used for experimental and other 
scientific purposes. 
Male large-white/Landrace healthy pigs (20–24 kg, 10 weeks old, SAC Commercial Ltd, 
Edinburgh, United Kingdom) on a 12-hour light/dark cycle, with free access to water and 
twice-daily food, were maintained at the Biological Procedures Unit, University of 
Strathclyde. All procedures were performed in accordance with local ethical and UK Home 
Office regulations. 
 
2.2.2 Bindarit Administration 
Bindarit, 2-methyl-2-[[1-(phenylmethyl)-1H-indazol-3-yl]methoxy] propanoic acid 
(MW 324.38), was synthesized by Angelini (Angelini Research Center-ACRAF, Italy). 
Pharmacokinetic studies in rodents show that bindarit is well absorbed when administered 
by oral route, and it has a mean half-life of ~9 h and, at dose regimen used in this study, 
reaches plasma levels in the range of 150-450 μM (Product data sheet, Angelini Research 
Center). 
Rats were treated with bindarit, suspended in 0.5% methylcellulose aqueous solution, at 
the dose of 100 mg/kg given orally, by gastric gavage, twice a day from 2 days before 
angioplasty up to 14 days after, whereas apoE¯/¯ mice were dosed (100 mg/kg/os/bid) from 
 26 
 
7 days before endothelial denudation up to 28 days after. In each experiment, control 
animals received an equal volume of methylcellulose (0.5 mL/100 g in rats; 0.1 mL/10 g in 
mice). 
Pigs were treated with bindarit at the dose of 25 mg/kg given orally twice a day (12-hour 
interval). Dosing started 2 days before stenting and continued daily for the 7 or 28 day 
follow-up period. The bindarit powder was mixed with yogurt and squirted into the pigs’ 
mouths. Control animals received vehicle alone (yogurt containing no bindarit). 
The dose regimen of bindarit was chosen based on earlier results from a swine 
renovascular hypertension model (Lin J et al., 2009; Zhu XY et al., 2009) and 
pharmacokinetic studies in male Göttingen minipigs (10–12 kg, Harlan) showing that 
bindarit is well absorbed when administered by the oral route. Single-dose oral 
administration of 25 mg/kg resulted in a Cmax level of 50 μg/mL (corresponding to 154 
μmol/L), Tmax 2 hours, and t½ ≈ 10 hours (Product Data Sheet, Angelini Research Center), 
corresponding to concentrations able to inhibit MCP-1 production and inflammation (Lin J 
et al., 2009; Zhu XY et al., 2009; Zoja C et al., 1998). 
   
2.2.3 Surgical procedures 
2.2.3.1 Rat carotid ballon angioplasty 
Rats were anaesthetized with an intraperitoneal injection of ketamine (100 mg/kg) 
(Gellini International) and xylazine (5 mg/kg) (Sigma). Endothelial denudation of the left 
carotid artery was performed with a balloon embolectomy catheter (2 F, Fogarty, Edwards 
Lifesciences) according to the procedure well validated in our laboratories (Maffia P et al., 
2006) 
Some animals were subjected to anaesthesia and surgical procedure without balloon 
injury (sham-operated group). Rats were euthanized 1, 7, 14, and 28 days after angioplasty. 
Blood and carotid arteries were collected and processed as described below. 
  
2.2.3.2 Wire-induced carotid injury in apoE¯/¯ mice 
ApoE¯/¯ mice were fed an atherogenic diet (21% fat, 0.15% cholesterol, 19.5% casein, 
wt/wt; TD88137, Mucedola) from 1 week before until 4 weeks after carotid injury 
performed as described previously (Jeremy JY et al., 2010), with minor modification. 
Briefly, mice were anaesthetized as described above, and endothelial injury of the left 
common carotid artery was performed with a 0.35 mm diameter flexible nylon wire 
introduced through the left external carotid artery and advanced to the aortic arch. The 
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endothelium was damaged by passing the wire through the lumen of the artery three times. 
ApoE¯/¯ mice were euthanized 7 and 28 days after wire injury. Blood and carotid arteries 
were collected and processed as described below. 
  
 2.2.3.3 Porcine coronary arteries stent implantation 
Pigs were premedicated with aspirin (150 mg oral, Teva, Leeds, United Kingdom) and 
clopidogrel (150 mg oral, Sanofi-Aventis, Guildford, United Kingdom) over a 24-hours 
period before surgery. Pigs were sedated by an injection of tiletamine/zolazepam (100 mg 
Zoletil IM, Virbac, Suffolk, United Kingdom) and propofol (30 mg Rapinovet IV, Schering-
Plough, Welwyn Garden City, United Kingdom). All animals were intubated and anesthesia 
maintained throughout the procedure using a mixture of isoflurane (1% to 2%, Abbott 
Laboratories Ltd., Maidenhead, UK) in oxygen/nitrous oxide. Unfractionated heparin (100 
U/kg IV, Leo Laboratories, Bucks, United Kingdom) was given at the start of the procedure. 
Access to the coronary arteries was achieved via the left femoral artery, using standard 6 
French sheaths and coronary guiding catheters. In the majority of animals, stents (Multi-
Link Vision, 3.5 x 15 mm, Abbott) were placed in 2 of the 3 coronary arteries (left anterior 
descending, left circumflex, and right coronary arteries) under fluoroscopic guidance. Nine 
bindarit-treated animals (16 stents) and ten control animals (17 stents) were used for the 
morphometric analysis. Six bindarit-treated animals (12 stents) and six control animals (12 
stents) were used for the proliferating cell nuclear antigen analysis. Five bindarit-treated 
animals (10 stents) and six control animals (12 stents) were used for evaluating the effect of 
bindarit on monocyte/macrophage infiltration. ECG and MAP were recorded continuously. 
Stents were deployed at inflation pressures necessary to produce a stent to artery ratio of 
1.2:1. After sheath removal, the femoral artery was ligated, and the leg wound was closed 
and sutured. All animals were given buprenorphine (0.15 mg of Vetergesic IM, Alstoe Ltd, 
York, United Kingdom) to provide analgesia and ampicillin (350 mg of Amfipen LA IM, 
Intervet, Welwyn Garden City, United Kingdom) for antibiotic cover, immediately after the 
procedure. Animals were recovered and received a normal diet, with supplementation of 75 
mg of aspirin orally every 2 days and 75 mg of clopidogrel orally every 2 days for the 
duration of the study. 
One control animal failed to develop vascular injury in both implanted stents and was 
excluded from the study. Pigs were euthanized 7 or 28 days after stent implantation, with an 
overdose of pentobarbital (200 mg/mL pentobarbitone, Merial, Harlow, United Kingdom) 
via the marginal ear vein, and the stented arteries were removed from the heart and flushed 
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with normal saline to remove non-adherent thrombus. The coronary arteries harvested 7 
days after stent implantation were divided into 2 parts at the center of the stent. The 
proximal part was used for protein extraction, and the distal portion was fixed in 10% 
formaldehyde and used for immunohistochemical staining. 
 
 2.2.4 Tissue processing and Morphometric Analysis of Injured Arteries 
For the evaluation of neointima formation, carotid arteries from rats or apoE¯/¯ mice 
were fixed by perfusion with phosphate-buffered saline (PBS; pH 7.2) followed by PBS 
containing 4% formaldehyde through a cannula placed in the left ventricle. Paraffin-
embedded sections were cut (6 μm thick) from the approximate middle portion of the artery 
and stained with haematoxylin and eosin. Ten sections from each carotid artery were 
reviewed and scored under blind conditions. The cross-sectional areas of media and 
neointima were determined by a computerized analysis system (LAS, Leica).  
Stented coronary arteries harvested at 28 days were fixed in formal saline (24 hours) and 
dehydrated in pure acetone before resin embedding in glycol methacrylate (Technovit 8100, 
Kulzer, Wehrheim, Germany) following the manufacturer’s instructions. Sections (4–12 in 
controls and 5–12 in bindarit) were obtained from the proximal to distal portion of the stent 
using a Buehler Isomet 1000 rotary precision saw (Buehler, Lake Bluff, IL) and mounted on 
a glass slide. Sections were then ground and polished using a Buehler Metaserv 2000 grinder 
to reduce the thickness to 10 μm and give a uniform surface for staining and microscopic 
evaluation. Sections were stained using hematoxylin/eosin to demarcate cell types, and 
images were acquired using a Leica DM LB2 microscope and Leica DFC320 digital camera. 
After digitalizing, histomorphometric measurements were performed with ImageJ (NIH 
Imaging, http://rsbweb.nih.gov/ij). Borders were manually traced for lumen area, area 
circumscribed by the internal elastic lamina (IEL), the border of the external elastic lamina 
(external elastic lamina area, vessel area) and stent circumference as the linear distance from 
strut to strut around the circumference of the stent (Suzuki T et al., 2001). The neointimal 
and medial areas were computed as follows: neointimal area = IEL area minus lumen area; 
medial area = external elastic lamina area minus IEL area. Furthermore, percentage area of 
stenosis was calculated as 100X (1 - lumen area/IEL area). Neointimal thickness (defined as 
the minimum distance between the strut and the lumen) was determined at each strut site and 
calculated as mean for each stented coronary segment. Results are expressed as the mean 
value from both stents per animal. 
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2.2.5 Injury and Inflammatory Score in Porcine Coronary Stent Model 
The injury score was calculated as previously reported by Gunn J et al. (2002). Briefly, 
we considered both deep injury and stretch as follows: 0 = no impression of metal on media; 
1 = deformation of the IEL by <45°; 2 = deformation of the IEL by >45°; 3 = rupture of the 
IEL; 4 = rupture of the external elastic lamina (that is complete medial rupture). 
The inflammatory score was calculated as previously reported by Kornowski R et al. 
(1998) Briefly, we considered the extent and density of the inflammatory infiltrate in each 
individual strut, and the grading used was as follows: 0 = no inflammatory cells surrounding 
the strut; 1 = light, noncircumferential lymphohistocytic infiltrate surrounding the strut; 2 = 
localized, moderate to dense cellular aggregate surrounding the strut noncircumferentially; 3 
= circumferential dense lymphohistiocytic cell infiltration of the strut. The injury and 
inflammatory score for each cross section were calculated as the sum of the individual injury 
or inflammatory scores, divided by the number of struts in the examined section. 
  
 2.2.6 Immunohistochemisty Analysis 
2.2.6.1 Proliferating Cell Nuclear Antigen (PCNA) Analysis in Injured Arteries 
Proliferating cell nuclear antigen (PCNA) analysis was used to quantify the proliferative 
activity of cells at the injury sites. 
After fixation in 10% formaldehyde of the coronary arteries harvested at day 7, the stent 
struts were gently removed with micro-forceps under a dissection microscope. The 
specimens were dehydrated, embedded in paraffin, and cut into 7-μm-thick slices. 
After antigen retrieval in citrate buffer, the sections from rat or mouse apoE¯/¯ carotid 
arteries and porcine coronary arteries, were incubated with monoclonal mouse anti-PCNA 
antibody (1:250, PC10, Sigma) and biotinylated anti-mouse secondary antibody (1:200, 
DakoCytomation, Milan, Italy). Slides were treated with streptavidin– horseradish 
peroxidase (DakoCytomation) and exposed to diaminobenzidine chromogen 
(DakoCytomation) with hematoxylin counterstain.  
Six sections from each rat carotid artery and ten random fields per section were reviewed 
and scored under blind conditions. Data are expressed as the percentage of total arterial 
(medial plus neointimal) PCNA positive cells 7 days after angioplasty. 
Ten sections from each mouse apoE¯/¯ carotid artery were reviewed and scored under 
blind conditions. Results are expressed as percentage of total PCNA-positive cells 7 days 
after wire injury. 
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Ten sections from each porcine coronary artery and ten random fields (X 20 objective) 
per section were reviewed and scored under blind conditions. Data are expressed as the 
percentage of total PCNA positive cells 7 days after stent implantation. 
 
2.2.6.2 MCP-1 Immunoistochemistry in rat injured carotid arteries 
Rat carotid arteries (1, 7, and 14 days after angioplasty, or naive) were snap-frozen in 
liquid nitrogen in OCT embedding medium (Tissue Tek, Sakura Finetek). Ten cross-sections 
were cut (6 mm) from the approximate middle portion of the artery and used for MCP-1 
detection. Sections were incubated with polyclonal goat anti-MCP-1 antibody (1:50, R-17, 
Santa Cruz) diluted in blocking buffer/0.3% Triton X-100 (MP Biomedicals) in PBS 
overnight before being washed in TNT wash buffer (Tris–HCl, pH 7.5, 0.15 M NaCl, and 
0.05% Tween 20; Sigma). Sections incubated with goat nonimmune serum were used as 
negative controls. Subsequently, sections were incubated with biotinylated anti-goat 
secondary antibody (1:400, DakoCytomation) diluted in blocking buffer/0.3% Triton X-100, 
washed in TNT wash buffer, treated with streptavidin–HRP, and exposed to 
diaminobenzidine chromogen with haematoxylin counterstain. The sections were 
photographed and the images were stored in the image analysis system (LAS, Leica). 
 
2.2.6.3 Immunohistochemisty analysis in injured apoE
-/-
 mouse carotid arteries 
Carotid arteries were snap-frozen in liquid nitrogen in OCT embedding medium. Fifteen 
cross-sections were cut (6 mm) from the approximate middle portion of the artery and used 
for MCP-1, a-smooth muscle actin (a-SMA), and macrophage detection by 
immunofluorescence. For staining, the sections were processed as described above and 
incubated with polyclonal goat anti-mouse MCP-1 antibody (1:50, M-18, Santa Cruz) or rat 
anti-F4/80 monoclonal antibody (1:50, clone BM8, Abcam) diluted in blocking buffer/0.3% 
Triton X-100 (MP Biomedicals) in PBS overnight before being washed in TNT wash buffer. 
Sections incubated with non-immune goat serum or an isotype-matched control antibody 
were used as negative controls. Subsequently, the sections were incubated with 1:75 Texas 
Reddonkey anti-goat IgG (Jackson ImmunoResearch Laboratories) or with 1:200 
biotinylated anti-rat secondary antibody (DakoCytomation), amplified with Tyramide Signal 
Amplification Systems (PerkinElmer), and revealed with streptavidin–FITC (1:50, 
DakoCytomation). Monoclonal anti-α-SMA FITC (1:250, clone 1A4, Sigma) was added in 
blocking buffer for 1 hour before washing as described above. DAPI was used to identify 
nuclei. Images were taken using an AxioCam HRc videocamera (Zeiss) connected to an 
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Axioplan fluorescence microscope (Zeiss) using the AxioVision 3.1 software. The 
neointimal areas stained for F4/80 were determined in digitized images (five sections per 
mouse), and positive areas for specific immunostaining were quantified (NIH Imaging; 
http://rsb .info.nih.gov/ij). Data are expressed as the percentage of the immunostained area 
per total neointimal area. Serial carotid paraffin-embedded sections were cut (5 mm) and 
used for detection of calponin (1:100, clone hCP, Sigma). Ten sections from each carotid 
artery were reviewed and scored under blind conditions. The number of calponin-positive 
cells in neointima was counted. 
 
2.2.6.4 Contractile Proteins Localization in rat carotid arteries 
Paraffin sections (6 μm) from rat carotid arteries (7, 14 and 28 days after angioplasty, or 
naïve animals) were deparaffinised and endogenous peroxidase activity was blocked by 
incubating with 0.3% H2O2 following antigenic recovery. The sections were incubated with 
the primary antibody against α-SMA (1:100), calponin (1:50) or SMemb (1:200) diluted in 
blocking buffer/0.3% Triton X-100 (MP Biomedicals) in PBS overnight before being 
washed in TNT wash buffer (Tris–HCl, pH 7.5, 0.15 M NaCl, and 0.05% Tween 20; 
Sigma). Sections incubated with isotype matched antibodies were used as negative controls. 
Subsequently, sections were incubated with biotinylated anti-mouse (1:500, 
DakoCytomation) diluted in blocking buffer 0.3% Triton X-100, washed in TNT wash 
buffer, treated with horseradish peroxidise labelled streptavidin, and exposed to 
diaminobenzidine chromogen with haematoxylin counterstain. The sections were 
photographed and the images were stored in the image analysis system (LAS, Leica). 
 
2.2.7 Evaluation of re-endothelialization in injured rat carotid arteries 
Re-endothelialization was assessed 2 weeks after balloon injury by staining with Evans 
Blue dye (0.5 mL of 0.5% Evans Blue dye iv; Sigma) as described previously (Asahara T et 
al., 1996). Planimetric analysis with an image analysis program (LAS, Leica) was 
performed. Re-endothelialization was expressed as the percentage of re-endothelialized area 
vs the total denuded area. To verify that the Evans Blue stain accurately depicted the 
presence or absence of endothelium, sections of completely or partially re-endothelialized 
carotid arteries (based on Evans Blue appearance) were stained with antibody to von 
Willebrand factor (vWF, Cytomation Dako) as described previously (Yue TL et al., 2000). 
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2.2.8 Total Tissue Extracts 
All the extraction procedures were performed on ice with ice-cold reagents. Briefly, 
frozen porcine coronary arteries or pooled carotid arteries (n = 2), were crushed into a fine 
powder in a mortar with a pestle under liquid nitrogen and resuspended in an adequate 
volume of Cell Extraction Buffer containing 100 mmol/L Tris, pH 7.4; 2 mmol/L Na3VO4; 
100 mmol/L NaCl; 1% Triton X-100; 1 mmol/L EDTA; 10% glycerol; 1 mmol/L EGTA; 
0.1% SDS; 1 mmol/L NaF; 0.5% deoxycholate; 20 mmol/L Na4P2O7, supplemented with 1 
mmol/L phenylmethylsulfonyl fluoride and Protease Inhibitor Cocktail (P2714) (Sigma, 
Dorset, United Kingdom) just before use and then centrifuged at 13000xg at 4 °C for 30 
minutes. Supernatant were transferred to fresh tubes and stored at -80 °C until the assays. 
Protein concentration was determined using the Bio-Rad protein assay kit (Bio-Rad). 
  
 2.2.9 Western blot Analysis on Injured Arteries 
The levels of PCNA and CD68 expression in total protein extracts from porcine 
coronary arteries were evaluated respectively 7 and 28 days after stent implantation. 
Equivalent amounts of protein (60 μg) from each sample were electrophoresed on a 10% 
discontinuous polyacrylamide gel. 
The levels of PCNA, CD68, α-SMA, calponin and SMemb were evaluated in total 
extracts from rat carotid arteries 7, 14, and 28 days after injury. Equivalent amounts of 
protein (50 μg) from each sample were electrophoresed on a 10% discontinuous 
polyacrylamide gel. 
After incubation with a primary antibody against PCNA (1:2000, Sigma-Aldrich), mouse 
anti-CD68 (1:1000, AbD Serotec), α-SMA (1:5000), calponin (1:3000) or SMemb (1:2000), 
the membranes were washed and  incubated with anti-mouse immunoglobulins coupled to 
peroxidase (1:2000). The immunocomplexes were visualised by the ECL 
chemiluminescence method and results were normalized to of the housekeeping protein β-
actin or glyceraldehyde-3-phosphate dehydrogenase (GAPDH). 
  
2.2.10 ELISA on animal tissues 
Rat carotid artery was crushed into powder and resuspended in 100 mL of lysis buffer 
(20 mM HEPES, 0.4 mM NaCl, 1.5 mM MgCl2, 1 mM EGTA, 1 mM EDTA, 1% Triton X-
100, and 20% glycerol) with protease inhibitors (1 mM DTT, 0.5 mM PMSF, 15 mg/mL 
Try-inhibitor, 3 mg/mL pepstatin-A, 2 mg/mL leupeptin, and 40 mM benzamidine). After 
centrifugation at 13 000 g at 48C for 30 min, MCP-1 in the supernatants was quantified 
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using an ELISA kit (OptEIATM, Biosciences). All measurements were performed in 
duplicate. The values were corrected by protein concentrations measured by the Bio-Rad 
protein assay kit (Bio-Rad). Serum MCP-1 levels (1, 7, and 14 days after angioplasty) were 
also measured in the same animals used above by ELISA (OptEIATM, Biosciences). The 
results are expressed as nanograms per millilitre. MCP-1 levels in rat carotid arteries 1, 7, 
and 14 days after balloon injury was quantified using an ELISA kit according to the 
manufacturer’s instructions (OptEIATM, Biosciences). All measurements were performed 
in duplicate. The values were corrected by protein concentrations measured by the Bio-Rad 
protein assay kit (Bio-Rad). 
MCP-1, total cholesterol, and triglyceride serum levels were also determined in apoE¯/¯ 
mice 28 days after wire injury, using enzymatic immunoassays according to the 
manufacturer’s instructions (OptEIATM, Biosciences; Serum Triglyceride Kit, Sigma; 
Cholesterol Assay Kit, Cayman Chemical). The results are expressed as pg/mL and mg/dL 
respectively. 
MCP-1 plasma levels were measured in pigs 28 days after stent implantation by ELISA 
according to the manufacturer’s instructions (Pig CCL-2 ELISA kit, Bethyl Laboratories, 
Montgomery, TX). The results are expressed as pg/mL 
 
2.2.11 Statistical Analysis 
Results are expressed as mean±SEM of n animals for in vivo experiments and 
mean±SEM of multiple experiments for in vitro assays. Student’s t-test was used to compare 
two groups and ANOVA (two tailed P-value) was used with the Dunnett post hoc test for 
multiple groups using Graph Pad Instat 3 software (San Diego, CA, USA). The level of 
statistical significance was 0.05 per test. 
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3. RESULTS 
 
3.1 Effect of bindarit on neointima formation in both rats and hyperlipidaemic mice 
3.1.1 Rat VSMC Proliferation and Migration 
Initiation and maintenance of  SMCs proliferation is a critical event in the pathogenesis 
of neointima formation. As shown in Figure 6A, bindarit at 100 and 300 μM significantly 
inhibited PDGF-BB-induced rat SMCs proliferation by 27% (P<0.05, n = 3) and 42% 
(P<0.01, n = 3), respectively. Similar results were obtained with apoE¯/¯ mice VSMC (data 
not shown). Another key mechanism of neointima formation is mitogen-mediated migration 
of SMCs. Therefore, we evaluated the effects of bindarit on PDGF-BB-induced rat SMCs 
chemotaxis. Bindarit inhibited significantly (P<0.01, n = 3) chemotactic migration at 100 
and 300 μM by 45 and 50%, respectively (Figure 6B). Moreover, bindarit (100 μM) also 
significantly reduced rat SMCs invasion (by 30%, P<0.01, n = 3, Figure 6C) through the 
Matrigel barrier which mimics extracellular matrix. Analysis of cell viability (>95%) 
demonstrated that it was not affected by bindarit at the concentrations used in this study 
(data not shown). 
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Figure 6 
(A) Effect of bindarit (10-300 µM) on rat SMC proliferation, (B) migration, and (C) invasion 
performed as described above. Results are expressed as mean±SEM from three separate 
experiments. *P<0.05, **P<0.01 vs platelet derived growth factor-BB (PDGF-BB); 
°°P<0.01, °°°P<0.001 vs unstimulated cells. 
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3.1.2 MCP-1 Production in rat SMC 
To determine whether the anti-proliferative and anti-migratory effects of bindarit were 
associated with MCP-1 inhibition, protein concentration of MCP-1 in the supernatant of 
cultured rat SMCs was determined by ELISA. As shown in Table 1, stimulation of SMCs 
with PDGF-BB (10 ng/mL) caused a time-dependent increased release of MCP-1 compared 
with that observed in unstimulated cells. When rat SMCs were stimulated with PDGF-BB in 
the presence of bindarit (10-300 μM), a concentration-related inhibition of MCP-1 
production was observed. 
 
 
MCP-1 
(ng/mL) 
   
 6 h 12 h 24 h 48 h 
Unstimulated cells 0.32 ± 0.02 3.2 ± 0.21 18.5 ± 0.9 34.1 ± 1.4 
PDGF-BB 10 ng/mL 3.1 ± 0.1°° 
20.8 ± 
1.58°° 
59.6 ± 0.4°° 142.6 ± 2.8°° 
+ bindarit 10 µM 3.0 ± 0.2 18.3 ± 1.2 
50.9 ± 
1.2** 
128.0 ± 
3.7** 
+ bindarit 30 µM 1.5 ± 0.1** 
13.7 ± 
0.5** 
42.8 ± 
0.6** 
87.3 ± 1.7** 
+ bindarit 100 µM 1.3 ± 0.2** 
11.9 ± 
0.4** 
34.0 ± 
1.0** 
80.1 ± 1.8** 
+ bindarit 300 µM 0.8 ± 0.1** 4.8 ± 0.5** 
29.3 ± 
1.1** 
72.1 ± 1.3** 
Table 1 
Effect of bindarit on MCP-1 production by platelet derived growth factor-BB (PDGF-BB)-
stimulated SMCs. Results are expressed as mean+SEM of three separate experiments 
performed in triplicate. °°P<0.01 vs unstimulated cells.**P<0.01 vs PDGF-BB. 
 
 
3.1.3 Neointima Formation in rat carotid arteries 
To determine the efficacy of a systemic treatment with bindarit for the limitation of 
neointimal hyperplasia, a rat carotid arterial injury model was used. A remarkable increase 
in the number of PCNA-positive cells was demonstrated in both the media and neointima 7 
days after injury in control rats, which was significantly reduced (P<0.001, n = 9) in the 
bindarit-treated group (200 mg/kg/day) by 54 and 30%, respectively (Figure 7A). Bindarit 
caused a significant inhibition of neointima formation by 39% (P<0.01, n = 19) at day 14 
compared with the control animals (Figure 7B). Medial area (0.124±0.003 mm
2
 in the sham 
group) was not affected by both vascular injury and bindarit. 
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 3.1.4 Monocytes/Macrophages Infiltration in rat carotid arteries 
Western blot analysis was performed to examine the effect of bindarit on the carotid 
monocyte/macrophage content. Monocyte/macrophage marker CD68 was highly expressed 
in carotid arteries 14 days after angioplasty when compared with that of sham-operated 
animals (Figure 7C). Bindarit significantly reduced CD68 levels as shown by relative 
densitometric analysis. 
  
 3.1.5 MCP-1 Production in rat carotid arteries 
We observed a significant time-dependent increase in MCP-1 production in the injured 
arteries at 1, 7, and 14 days after angioplasty when compared with that of sham-operated 
animals (Figure 7D). Bindarit was able to inhibit the MCP-1 protein expression throughout 
the time course considered, by 31% (P<0.05; n = 5), 38% (P<0.05; n = 5), and 49% 
(P<0.001; n = 5) at 1, 7, and 14 days after injury, respectively. In the contralateral carotid 
artery, no significant changes were observed throughout the observation period compared 
with those measured in sham-operated animals. In carotid arteries from naïve animals, the 
levels of MCP-1 measured were 0.74±0.34 ng/mg (n = 5). 
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Figure 7 
(A) Photomicrographs showing the effect of bindarit (200 mg/kg/day) on PCNA-positive 
cells in rat carotid arteries at day 7 after injury (magnification ×400). Results are expressed 
as mean±SEM of the percentage of total medial and neointimal cells positive for PCNA, 
where n = 9 rats for each group. ***P<0.001 vs control group. (B) Photomicrographs 
showing the effect of bindarit (200 mg/kg/day) on neointima formation in rat carotid arteries 
14 days after balloon injury (magnification ×100). Results are expressed as mean±SEM, 
where n = 15-19 rats. **P<0.01 vs control group. (C) Effect of bindarit (200 mg/kg/day) on 
monocyte/macrophage marker CD68 protein expression in carotid arteries 14 days after 
angioplasty. Equal loading was confirmed by β-acting staining. Results are expressed as 
mean±SEM of three separate experiments. **P<0.01 vs control group. (D) Effect of bindarit 
(200 mg/kg/day) on MCP-1 expression in rat carotid arteries 1, 7, and 14 days after balloon 
injury evaluated by ELISA. Results are expressed as mean±SEM of MCP-1 levels 
normalized with protein concentrations, where n = 5. *P<0.05; ***P<0.001 vs control 
group; °°°P<0.001 vs sham-operated animals. 
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 3.1.6 MCP-1 Localization in rat carotid arteries 
Non-injured carotid arteries lacked immunoreactivity for MCP-1, whereas injured 
arteries stained strongly for MCP-1 (Figure 8). Negative controls showed no signal. MCP-1-
positive staining was detectable in media of injured vessel from days 1 up to 14 and in 
neointimal cells at days 7 and 14. MCP-1 localization was not modified by bindarit, whereas 
the drug treatment resulted in a lower MCP-1 expression in both media and neointima 
(Figure 8). 
 
 
Figure 8 
Immohistochemical localization of MCP-1 expression in rat carotid arteries 1, 7, and 14 
days after angioplasty. 
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 3.1.7 Re-endothelialization in rat carotid arteries 
Evans Blue staining identifies segments of injured carotid arteries that have not been re-
endothelialized. As shown in Figure 9, the presence of intact endothelium in the carotid 
artery of naïve rats was demonstrated by the absence of Evans Blue staining. 
Immunohistochemical staining with antibody to vWF verified the presence of endothelium. 
In contrast, the entire area of the artery harvested 1 day after injury was stained by Evans 
Blue. The absence of positive staining with antibody to vWF confirmed the observation. 
Analysis of samples at 2 weeks from angioplasty showed that bindarit treatment did not 
affect re-endothelialization of arteries when compared with control animals. 
  
 3.1.8 MCP-1 Serum Levels in rats 
A time-dependent increase in MCP-1 serum concentration was observed in rats 
subjected to angioplasty (Table 2). Bindarit caused a significant inhibition of MCP-1 serum 
levels at day 1 by 20% (P<0.05, n = 10) and at days 7 and 14 by 30% (P<0.001, n = 10) 
compared with their respective control groups. In naïve animals, the MCP-1 serum level was 
29.4±3.0 ng/mL (n = 5). 
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Figure 9 
Extent of re-endothelialization in injured carotid arteries evaluated by Evans Blue staining. 
Representative arteries harvested from naïve animals, as well as 1 and 14 days after carotid 
injury in vehicle- or bindarit-treated rats. Evans Blue staining identifies segments of each 
artery that have not been recovered by endothelium. Immunohistochemical staining with 
antibody to vWF verified the presence of endothelium. Re-endothelialization was expressed 
as the percentage of re-endothelialized area vs the total denuded area (bottom panel) (n = 5). 
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 MCP-1 (ng/mL)   
Group 1-day 7-day 14-day 
Sham-operated 37.1 ± 2.4 35.4 ± 1.2 32.8 ± 2.7 
Control 69.2 ± 3.5°° 51.4 ± 2.2°° 53.7 ± 3.9°° 
Bindarit 200 mg/kg/day 55.6 ± 3.0* 36.2 ± 2.4*** 37.2 ± 2.1*** 
Table 2 
Effect of bindarit on MCP-1 serum levels in rats. Results are expressed as mean±SEM, 
where n = 5–10 rats per each time point considered. °°P<0.01 vs. sham-operated 
animals.*P<0.05; ***P<0.001 vs control group. 
 
 
3.1.9 Neointima Formation in apoE¯/¯ mice 
To evaluate the effect of bindarit after arterial injury in hyperlipidaemic animals, carotid 
endothelial denudation was performed in apoE¯/¯ mice fed an atherogenic diet. Seven days 
after injury, the number of PCNA-positive cells was significantly reduced (42%, P<0.05, n = 
10) by treatment with bindarit (200 mg/kg/day) compared with control mice (Figure 10A). 
Neointimal area was reduced by 47% in apoE¯/¯ mice treated with bindarit compared with 
control mice 28 days after injury (Figure 10B). Moreover, the apoE¯/¯ mice receiving 
bindarit showed a 66% reduction in the relative content of F4/80-positive macrophages and 
a 30% reduction in the number of SMCs in neointimal lesion (Figure 10C and 10D). 
Injured carotid arteries stained strongly for MCP-1 detectable in media and neointima 28 
days after injury. Co-localization of MCP-1 and α-actin was evident in both media and 
neointima. MCP-1 localization was not modified by bindarit, but again the drug reduced 
both medial and neointimal MCP-1 expression (Figure 10E). 
Total cholesterol levels did not differ between groups (1036±38 mg/dL in bindarit-
treated group, n=10 vs 1167±50 mg/dL in control group, n = 10), whereas triglyceride levels 
were significantly lower (P<0.05) in bindarit-treated animals (191.6±21.3 mg/dL, n = 10) 
than in the control group (260.7±20.6 mg/dL, n = 10). Moreover, bindarit caused a 
significant inhibition (P<0.01) of MCP-1 serum levels by 42% (131.0±15.6 pg/mL in 
bindarit-treated group, n = 10 vs 224.8±28.3 pg/mL in control group, n = 10; P<0.01). 
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Figure 10 
(A) Photomicrographs showing the effect of bindarit (200 mg/kg/day) on PCNA-positive cells in 
apoE
−/−
 mice 7 days after injury (magnification ×400). Results are expressed as mean±SEM of the 
percentage of total PCNA-positive cells, where n = 10 rats for each group. *P<0.05 vs control group. 
(B) Photomicrographs showing the effect of bindarit (200 mg/kg/day) on neointima formation in 
apoE
−/−
 mice 28 days after carotid injury (magnification ×100). Results are expressed as mean±SEM, 
where n = 10 for each group; **P<0.01 vs control group. (C) Photomicrographs showing the effect 
of bindarit (200 mg/kg/day) on macrophage content in carotid arteries 28 days after injury 
(magnification ×400). Results are expressed as mean±SEM of the percentage of F4/80 
immunostained area per total neointima area, where n = 10 for each group; ***P<0.001 vs control 
group. (D) Photomicrographs showing the effect of bindarit (200 mg/kg/day) on neointimal SMCs 
content in carotid arteries 28 days after injury (magnification ×100). Results are expressed as 
mean±SEM of the calponin-immunostained cell number, where n = 10 for each group; *P<0.05 vs 
control group. (E) Immunofluorescence visualization of α-SMA (green) and MCP-1 (red) in mouse 
carotid arteries 28 days after injury. DAPI (blue) was used to locate nuclei. Co-localization of MCP-
1 and α-actin (yellow) was evident in some cells in both media and neointima (magnification ×200) 
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3.2 Effect of bindarit on in-stent stenosis in porcine coronary arteries 
 3.2.1 Morphometric Analysis 
Representative stented artery sections obtained 28 days after implantation are shown in 
Figure 11. Morphometric assessment showed a significant reduction in neointimal area 
(4.03±0.46 vs 6.65±0.44 mm
2
, P<0.001) (Figure 12A), neointimal thickness (270.2±26.92 vs 
551.06±49.94 μm, P<0.001) (Figure 12B), percentage of stenosis (47.56±3.42% vs 
74.97±2.71%, P<0.001) (Figure 12C), and inflammatory score (1.10±0.06 vs 1.83±0.11, 
P<0.001) (Figure 12D) in the bindarit-treated group compared with control animals. 
Moreover, in the bindarit-treated group, the lumen area was significantly increased 
compared with the control group (4.43±0.33 vs 2.12±0.15 mm
2
, P<0.001) (Figure 2E). No 
significant differences were detectable in vessel area (10.48±0.56 vs 11.05±0.35 mm
2
), IEL 
area (8.47±0.50 vs 8.76±0.31 mm
2
), or medial area (2.01±0.08 vs 2.28±0.14 mm
2
). 
Importantly, there was no significant difference in the injury score (2.31±0.11 vs 2.23±0.13) 
(Figure 12F) and stent circumference (9.53±0.16 vs 9.55±0.28 mm
2
) between the 2 groups, 
indicating and that experimental and control animals had a similar degree of injury and 
complete stent deployment. 
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Figure 11 
A and B, Representative photomicrographs (hematoxylin/eosin staining) showing the effect 
of bindarit on in-stent stenosis 28 days after stent deployment (A: control group; B: 
bindarit). Scale bar = 1 mm. C and D, Representative photomicrographs showing the 
reduction in inflammatory cell influx in the bindarit-treated group (D) vs control group (C). 
Scale bar = 100 μm 
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Figure 12 
Effect of bindarit on neointimal area (A), neointimal thickness (B), percentage of stenosis 
(C), inflammatory score (D), lumen area (E), and injury score (F). Data per single animal 
and means (bars) are presented. ***P<0.001 vs control group. ns indicates not significant. 
 
 
3.2.2 In Vivo Proliferation 
Treatment with bindarit significantly reduced (by 45%, P<0.05) the number of PCNA-
positive cells in the artery 7 days after stent implantation compared with control group 
(Figure 13A and 13B). Results were also confirmed by Western blot analysis. (Supplemental 
Figure I, available online at http://atvb.ahajournals.org).  
 
 3.2.3 Monocyte/Macrophage Infiltration in porcine coronary arteries 
Western blot analysis was performed to examine the effect of bindarit on the 
monocyte/macrophage infiltration. The monocyte/ macrophage marker CD68 was highly 
expressed in coronary arteries 28 days after stent implantation. Bindarit significantly 
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reduced (by 55%, P<0.01) CD68 levels as shown by relative densitometric analysis (Figure 
13C and 13D). 
 
 
 
 
 
Figure 13 
(A) Representative photomicrographs of proliferating cell nuclear antigen (PCNA)–stained 
coronary arteries at day 7 after stent implantation (magnification ×200). Scale bar = 100 μm. 
(B) Graph showing the effect of bindarit on cell proliferation in vivo. Results are expressed 
as percentage of total arterial (medial plus neointimal) cells positive for PCNA, as described 
in Methods. Data per single animal and means (bars) are presented. (C) Representative blot 
showing the effect of bindarit on CD68 expression in the protein extract of single coronary 
arteries 28 days after stenting. (D) Densitometric analysis of CD68 expression levels 
normalized to protein levels of β-actin. Data per single animal and means (bars) are 
presented. *P<0.05 and **P<0.01 vs control group. 
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 3.2.4 MCP-1 Plasma Levels in pigs 
A significant increase (P<0.01) in MCP-1 plasma concentration was observed in pigs 
subjected to stenting compared with the naïve animals (1903.05±172.64 pg/mL, n = 9, vs 
885.41±26.74 pg/mL, n = 5). Bindarit caused a significant (P<0.05) inhibition of MCP-1 
plasma levels at day 28 by ≈30% (1369.45±76.13 pg/mL, n = 7) (Figure 14). 
 
 
  
 
 
Figure 14 
Effect of bindarit on monocyte chemotactic protein-1 (MCP-1) plasma levels in pigs 28 days 
after stent implantation. °°P<0.01 vs naïve animals, *P<0.05 vs control group. 
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3.2.5 Porcine SMC Proliferation 
As shown in Figure 15, bindarit at 100 and 300 μmol/L significantly inhibited TNF-α-
induced porcine SMC proliferation by 33% band 50% (P<0.01, n = 3), respectively. Cell 
viability (>95%) was not affected by bindarit at the concentrations used in this study (data 
not shown). 
 
 
 
 
 
Figure 15 
Effect of bindarit (10-300 μmol/L) on tumor necrosis factor-α (TNF-α)–induced porcine 
smooth muscle cell proliferation. Results are expressed as mean±SEM of three separate 
experiments run in triplicate. °°P<0.01 vs unstimulated cells, **P<0.01 vs TNF-α. 
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3.2.6 MCP-1 Production in porcine SMC 
To determine whether the in vitro antiproliferative effect of bindarit was associated with 
MCP-1 inhibition, MCP-1 protein concentration was determined by ELISA in the 
supernatants of cultured primary porcine SMCs. As shown in the Table 3, stimulation of 
SMCs with TNF-α (50 ng/mL) caused an increase in release of MCP-1 compared with 
unstimulated cells. When porcine SMCs were stimulated with TNF-α in the presence of 
bindarit (10–300 μmol/L), a significant inhibition of MCP-1 production was observed at 100 
and 300 μmol/L. 
 
 MCP-1 
(pg/mL) 
   
 12 h 24 h 48 h 72 h 
Unstimulated cells 242±32 1044±77 1906±150 2520±164 
TNF-α 50 ng/mL 1840±192* 3817±215* 5120±220* 5354±161* 
+ bindarit 10 μmol/L  1637±123 3450±199 5450±310 6030±358 
+ bindarit 30 μmol/L  1701±51 3920±257 4770±353 5389±266 
+ bindarit 100 μmol/L  1241±55† 3046±152‡ 4080±144‡ 3782±116† 
+ bindarit 300 μmol/L  1088±36† 2430±133† 3400±174† 2824±110† 
Table 3 
Effect of bindarit on MCP-1 Production by TNF-α-Stimulated Porcine SMC. Results are 
expressed as mean±SEM of three experiments run in triplicate. *P<0.01 vs unstimulated 
cells.†P<0.01 vs TNF-α; ‡P<0.05 vs TNF-α. 
 
 
 3.3 Effect of Bindarit on Human CASMC Proliferation, Migration and Phenotypic 
Switching 
3.3.1 Contractile Proteins Expression in CASMCs 
CASMCs were stimulated with TNF-a (30 ng/mL) or FBS (5%) for 48 hours and the 
lysates from these cells were subjected to Western blot analysis. As shown in Figure 16, 
bindarit significantly reduced the expression of SMemb in both TNF-α-stimulated cells (by 
29% P<0.05 and 53% P<0.01, at 100 and 300 μM respectively) and FBS-stimulated cells 
(by 20% P<0.01 at 300 μM). The differentiated state of CASMCs induced by bindarit was 
also confirmed by the significant increased expression of α-SMA in both TNF-α-stimulated 
cells (by 87% P<0.05 and 132% P<0.01, at 100 and 300 μM respectively) and FBS-
stimulated cells (by 69% P<0.01 at 300 μM). Treatment with bindarit at 300 μM also 
significantly increased calponin expression when compared with both TNF-α-stimulated 
cells by 172% (P<0.05) and FBS-stimulated cells by 100% (P<0.01). 
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Figure 16 
Effect of bindarit on contractile proteins expression in CASMCs. Representative Western 
blots and relative densitometric analysis showing the effects of bindarit (100 and 300 µM) 
on contractile proteins expression levels modulated by (A) TNF-α (30 ng/mL) or (B) FBS 
(5%). Results are expressed as mean±SEM of three separate experiments run in triplicate. 
°°P<0.01 vs unstimulated cells; *P<0.05, **P<0.01 vs untreated cells 
 
 
3.3.2 CASMCs Morphological Changes induced by FBS 
In addition to SMC-specific protein expression we examined SMC morphology. After 48 
hours of stimulation with FBS (5%) the CASMCs were characterized by a flattened 
morphology as result of the dedifferentiation to a synthetic phenotype (Figure 17). Bindarit 
(300 μM) induced an elongated spindle-shaped phenotype, typical of a differentiated state 
(Figure 17). 
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Figure 17 
Effect of bindarit on morphological changes induced by FBS in CASMCs. Phase-
contrast photomicrographs of CASMCs cultured in medium with 5% FBS for 48 hours with 
or without bindarit (300 μM) 
 
 
3.3.3 CASMC Proliferation 
SMCs plasticity exhibited in response to vascular injury, is characterized by both loss of 
VSMC-specific proteins expression and the increase in the proliferation. As shown in Figure 
18A, bindarit at 10, 30, 100, and 300 μM significantly (P<0.01) inhibited TNF-α (30 
ng/mL)-induced CASMC proliferation by 24%, 39%, 52% and 54%, respectively. Similar 
inhibitory effects of bindarit were observed in FBS (5%)- stimulated CASMCs (Figure 
18A). 
We also evaluated CASMC proliferation by directly counting the cells (Figure 18B). 
Bindarit, which was ineffective at 10 μM, significantly (P<0.01) inhibited the TNF-α-
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induced CASMC number increase by 24%, 32% and 40%, at 30, 100, and 300 μM 
respectively. Similar inhibitory effects of bindarit were observed when FBS was used as 
stimulant (Figure 18B). Bindarit alone (300 μM) had no effect on cell proliferation/viability 
(Figure 18A and 18B). 
 
 3.3.4 CASMC Migration and Invasion 
The higher proliferation rate of dedifferentiated SMCs is accompanied by increased 
mitogen-mediated migration. Therefore, we evaluated the effect of bindarit (10–300 μM) on 
TNF-α-induced VSMC chemotaxis. Bindarit significantly (P<0.01) inhibited chemotactic 
migration at 100 and 300 μM by 30% and 55%, respectively (Figure 18C). Moreover, 
bindarit (300 μM) significantly (P<0.01) reduced CASMC invasion by 50% through the 
Matrigel barrier which mimics extracellular matrix (Figure 18D). Bindarit alone (300 μM) 
had no effect on both migration and invasion (data not shown). 
 
  
 
 
Figure 18 
Effect of bindarit on CASMC proliferation, migration and invasion. CASMC 
proliferation assessed by MTT assay (A) and by cell counting expressed as number of cells 
per field (B). Effect of bindarit on CASMC migration (C) and invasion (D). Results are 
expressed as mean±SEM of three separate experiments run in triplicate. °°P<0.01, 
°°°P<0.001 vs unstimulated cells; **P<0.01 vs TNF-α-stimulated cells; #P<0.05, ###P<0.001 
vs FBS-stimulated cells. 
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3.3.5 MMP-2 and MMP-9 Activity in CASMCs 
Subconfluent cultures of CASMCs were exposed to TNF-α (30 ng/mL) for 24 hours in 
the presence or absence of bindarit (300 μM) to assess gelatinase production. Gelatin 
zymography of control supernatants showed the constitutive release of the latent form of 
matrix metalloproteinase 2 (MMP-2), visualized as a bands at 72 kDa and 68 kDa. Neither 
the stimulation with TNF-α, nor the treatment with bindarit significantly modified the 
release of the active form (62 kDa) (Figure 19). The stimulation with TNF-α significantly 
(P<0.01) induced the release of MMP-9 (92 kDa) which was significantly (P<0.05) 
inhibited by bindarit (Figure 19). 
 
 
 
 
 
Figure 19 
Effect of bindarit on MMP-2 and MMP-9 activity. Representative gel zymography of 
conditioned medium from TNF-α (30 ng/mL)-stimulated CASMCs and relative 
densitometric analysis showing the effect ofbindarit (300 µM) on MMP-9 activated form 
and both MMP-2 latent (white columns) and activated (black columns) forms. Results are 
expressed as mean±SEM of three experiments. °°P<0.01 vs unstimulated cells; °P<0.05 vs 
TNF-α-stimulated cells. 
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3.3.6 MCP-1 and MCP-3 Production in CASMCs 
The effect of bindarit on MCP-1 and MCP-3 production by CASMCs was determined by 
ELISA. As shown in table 4, stimulation of CASMCs with TNF-α (30 ng/mL) or FBS (5%) 
caused a time-dependent increase of MCP-1 levels compared with unstimulated cells. 
Bindarit (10–300 μM) caused a significant concentration-related inhibition of MCP-1 
production. As shown in table 5, bindarit (30-300 μM) significantly reduced MCP-3 
production in TNF-α (30 ng/mL) stimulated CASMCs. FBS (5%) had no effect on MCP-3 
production (data not shown). Bindarit alone (300 μM) did not significantly affect basal 
MCP-1 or MCP-3 levels (table 4 and 5). 
  
 MCP-1 (ng/mL)   
 6 h 12 h 24 h 
Unstimulated cells 0.1±0.01 0.4±0.04 2.1±0.02 
Bindarit 300 µM 0.1±0.01 0.4±0.02 2.0±0.03 
TNF-α 30 ng/ml 1.6±0.07°° 3.0±1.09°° 13.1±0.12°° 
+ bindarit 10 µM 1.5±0.01 2.4±0.04** 11.5±0.15** 
+ bindarit 30 µM 1.4±0.01* 2.1±0.02** 10.8±0.10** 
+ bindarit 100 µM 1.3±0.02** 1.8±0.05** 10.3±0.29** 
+ bindarit 300 µM 1.1±0.06** 1.5±0.05** 8.0±0.05** 
FBS 5% 1.5±0.22 5.5±0.26
+++
 23.5±1.89
+++
 
+ bindarit 10 µM 1.5±0.29 4.7±0.61 22.5±1.56 
+ bindarit 30 µM 1.4±0.64 3.4±0.75 15.8±2.18
#
 
+ bindarit 100 µM 1.3±0.74 2.6±0.55
##
 10.5±0.87
###
 
+ bindarit 300 µM 1.0±0.34 2.5±0.30
##
 8.8±1.32
###
 
Table 4 
Effect of bindarit on MCP-1 production by TNF-α- or FBS-stimulated CASMCs. 
Results are expressed as mean ± SEM of three separate experiments run in triplicate. 
°°P<0.01, 
+++
P<0.001vs unstimulated cells; *P<0.05, **P<0.01vs TNF-α-stimulated cells; 
#
P<0.05, 
##
P<0.01,
 ###
P<0.001 vs FBS-stimulated cells. 
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 MCP-3 (pg/mL)   
 6 h 12 h 24 h 
Unstimulated cells 70.0±8.00 164.3±40.31 211.3±44.49 
Bindarit 300 µM 90.3±9.40 178.3±53.35 210.3±52.61 
TNF-α 30 ng/ml 116.9±25.71 501.0±78.48°° 714.3±87.83°°° 
+ bindarit 10 µM 113.3±16.13 428.0±46.46 671.3±99.47 
+ bindarit 30 µM 114.7±18.17 438.0±69.79 477.7±34.80 
+ bindarit 100 µM 110.0±20.30 286.0±49.00 440.3±31.84 
+ bindarit 300 µM 104.3±21.53 164.7±10.81* 151.3±6.36*** 
Table 5 
Effect of bindarit on MCP-3 production by TNF-α-stimulated CASMCs. Results are 
expressed as mean±SEM of three separate experiments run in triplicate. °°P<0.01, 
°°°P<0.001 vs unstimulated cells; *P<0.05, **P<0.01, ***P<0.001 vs TNF-α-stimulated 
cells. 
 
 
 3.3.7 Contractile Proteins Expression in rat carotid arteries 
As shown in Figure 20A, treatment with bindarit significantly reduced the expression of 
SMemb at 14 and 28 days (by 31%, P<0.001 and 37%, P<0.05, respectively) and increased 
the expression of calponin at 7 and 14 days (by 19%, P<0.05 and 47%, P<0.001). Bindarit 
also increased the expression of α-SMA at 14 and 28 days (by 13%, P<0.05 and 8%, 
P<0.01, respectively) and, as previously demonstrated, reduced the expression of PCNA at 7 
days (by 44%, P<0.01) (Figure 20B). 
Localization of contractile proteins in rat carotid arteries was performed by 
immunohistochemistry to determine the temporal expression and cellular localization. α-
SMA resulted highly expressed in the medial SMCs of non-injured carotid sections (data not 
shown), while negative control IgG showed no signal (data not shown). At day 7, medial 
SMCs, close to the lumen, started to lose α-SMA staining, as consequence of changes in 
phenotype. At day 14, SMCs in the media and neointima, although stained with the anti-α-
SMA antibody, showed weaker signal than the medial SMCs at day 7. At day 28, the α-
SMA resulted highly expressed in the medial SMCs, instead the expression in the neointimal 
cells resulted still weak or absent. Although bindarit did not modify α-SMA localization, it 
determined a higher α-SMA expression in both media and neointima, at all time points 
considered (Figure 21A). Non-injured carotid sections lacked immunoreactive SMemb (data 
not shown). In contrast, injured carotid arteries showed a remarkable number of cells in the 
media and neointima strongly positive for SMemb, at all time points considered, while 
negative control IgG showed no signal (data not shown). The treatment with bindarit 
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reduced the number of the SMemb-positive cells at day 7 and, more interesting, the SMemb-
positive cells resulted absent in the media at day 14 and 28 (Figure 21B). Immunoreactivity 
for calponin was visible in the medial SMCs of non-injured carotid sections (data not 
shown), while negative control IgG showed no signal (data not shown). At all time points 
considered, the injured arteries lacked immunoreactive calponin. Intriguingly, at day 7 and 
day 14, the vessels from bindarit-treated rats showed calponin signal in the medial SMCs 
(Figure 21C). 
 
 
 
 
 
Figure 20 
Effect of bindarit on contractile protein expression in rat carotid arteries. A and B. 
Representative Western blots and relative densitometric analysis showing the effect of the 
oral administration of bindarit (200 mg/Kg/day) on SMemb, calponin, α-SMA and PCNA 
expression levels in rat carotid arteries at days7, 14 and 28 days after injury. Results are 
expressed as mean ± SEM, where n = 4 pools. *P<0.05, **P<0.01 and ***P<0.001 vs 
control group. 
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Figure 21 
Effect of bindarit on contractile proteins localization in rat carotid arteries. 
Immohistochemical localization of α-SMA (A), SMemb (B) and calponin (C) expression in 
rat carotid arteries 7, 14 and 28 days after angioplasty. Bar = 100 μm. 
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4. DISCUSSION 
 
The results provided in this thesis show that bindarit given systemically significantly 
reduced neointimal formation in animal models of arterial injury by inhibiting SMC 
proliferation/migration, and macrophage infiltration; these effects correlated with a 
reduction in MCP-1 synthesis.  
Bindarit is an original compound selected by screening a series of indazolic derivatives 
endowed with peculiar anti-inflammatory activity associated with a selective inhibition of a 
subfamily of CC inflammatory chemokines, including MCP-1/CCL2, MCP-3/CCL7, and 
MCP-2/CCL8, showing no effect on other CC and CXC chemokines such as MIP-1a/ CCL3, 
MIP-1b/CCL4, MIP-3/CCL23, RANTES/CCL5, and IL8/ CXCL8 (Zoja C et al., 1998; 
Guglielmotti A et al., 2002; Bhatia M et al., 2005; Bhatia M et al., 2008; Mirolo M et al., 
2008).  
After vascular damage, the rat carotid artery develops neointimal formation, mainly due 
to proliferation and migration of SMCs, that causes a clear narrowing of the vessel lumen. 
Neointima formation contributes to the development of restenosis after coronary artery 
angioplasty, with or without stenting, in which a pivotal mechanism is represented by the 
loss of differentiation of SMCs that were able to proliferate and migrate (Owens GK et al., 
2004).  
It is well known that among pro-inflammatory CC chemokines, MCP-1 is implicated in 
all these processes and the source of this chemokine is likely to include the major cells in 
injured arteries, such as endothelial cells, SMCs, and macrophages (Charo IF and Taubman 
MB, 2004). 
In injured carotids arteries from rats treated with bindarit, a significant inhibition of 
neointima formation associated with a reduced MCP-1 production was observed. Bindarit 
did not modify MCP-1 localization but reduced MCP-1 expression in both media and 
neointima. Moreover, bindarit caused significant inhibition of MCP-1 serum levels. 
Increased levels of circulating MCP-1 in animals subjected to vascular injury are in keeping 
with an active role for this cytokine in tissue pathogenesis and correlate with 
epidemiological evidence showing higher MCP-1 plasma levels associated with human 
restenosis (Cipollone F et al., 2001; Martinovic I et al., 2005). 
Bindarit showed in vivo anti-proliferative effects. Thus, bindarit diminished the number 
of PCNA-positive proliferating cells in the media and intima 7 days after rat balloon 
 60 
 
angioplasty, concomitantly with the beginning of neointimal formation, without affecting re-
endothelialization evaluated 14 days after injury.  
It is well known that MCP-1 activity is in part due to recruitment of 
monocytes/macrophages that are responsible for local production of cytokines, but MCP-1 
may also directly induce SMC proliferation and migration through cell cycle proteins and 
intracellular proliferative signals (Selzman CH et al., 2002; Massberg S et al., 2003; Parenti 
A et al., 2004). 
Our results also showed that bindarit reduced monocytes/ macrophages recruitment in 
injured rat carotid arteries. The rat balloon angioplasty model could be considered ideal to 
study the proliferation of SMCs in vivo; however, it is not an ideal model for the study of 
monocytes/macrophages recruitment, considering the injury is performed in a non-
atherosclerotic arterial bed (Reidy MA et al., 1992; Roque M et al., 2000). 
It is well known that hypercholesterolaemia, a potent trigger of vessel wall inflammation 
in atherosclerosis, induces MCP-1 expression in SMCs and upregulates CCR2 in human 
monocytes, enhancing monocyte recruitment after arterial injury and thus mediates the 
exacerbation of neointimal growth (Yu X et al., 1992; Han KH et al., 1998; Oguchi S et al., 
2000). In our experiments, no clear atherosclerotic lesions were detectable in the aortic root 
of mice 28 days after injury. However, we and others have demonstrated that lymphocytes 
already reside into the adventitia of arterial wall of apoE¯/¯ mice even before the onset 
atherosclerosis (Galkina E et al., 2006; Maffia P et al., 2007). In this light, the 
hyperlipidaemic mice tool represents a step forward to the rat balloon angioplasty model, 
allowing us to study the effect of bindarit in the contest of increased vascular inflammation. 
Our results clearly demonstrated that bindarit reduced neointima formation by reducing 
proliferating rate and macrophage infiltration, effects associated with a reduced expression 
of MCP-1 in injured vessels. In hypercholesterolaemic rabbits, gene transfer of a plasmid 
coding for a mutant form of MCP-1 appeared to reduce neointima formation after balloon 
injury, mainly inhibiting macrophage infiltration to the injured vessels (Mori E et al., 2002). 
Similarly, in hypercholesterolaemic apoE¯/¯ mice also deficient in CCR2, neointimal 
lesions after wire injury of the carotid artery were diminished and showed a marked 
reduction in macrophage content compared with apoE¯/¯/CCR2
+
/
+
 mice (Schober A et al., 
2004). 
However, although small animal models of neointimal formation have several 
advantageous characteristics (eg, low cost, ready availability, small size that limits the 
quantities of investigational drugs required for in vivo use), on many occasions they lack 
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efficacy in predicting the success of interventions to inhibit restenosis in humans (Johnson 
GJ et al., 1999; Jeremy JY et al., 2010; Touchard AG et al., 2006). Therefore, we evaluated 
the efficacy of bindarit in the preclinical model of in stent stenosis in pigs. 
Bindarit given orally significantly reduced in-stent stenosis in the porcine coronary stent 
model. When compared with the controls, stented arteries from bindarit-treated animals 
showed a significant reduction of morphometric percentage stenosis area, from 75% to 
47.5%, a decrease of 37%. Seventy-five percent of the stenosis area in the control group was 
a higher value than other reports in the literature (Kasai T et al., 2008; Heldman AW et al., 
2001). However, as shown by our injury score, no or minimal damage was induced to the 
media. According to the Gunn J (2002) scoring system, an average value of ≈2.2 indicates 
an IEL deformed >45° in most of the samples analyzed in the absence of medial injury. 
Injury scores, external elastic lamina area, IEL area, and stent circumference were similar in 
both groups, confirming the homogeneity of the analyzed data in our model. In stented 
coronary arteries from animals treated with bindarit, neointimal area was significantly 
inhibited by 40% compared with control animals. Importantly, bindarit shows effects similar 
to those of paclitaxel- and sirolimous-coated stents on neointima formation in porcine 
models (Suzuki T et al., 2001; Heldman AW et al., 2001). A moderate inflammation was 
also observed in peri-stent areas, as assessed by the inflammatory score, and this was 
reduced by ≈40% in stented arteries from bindarit-treated animals. 
Neointimal hyperplasia contributes to the development of in-stent restenosis (Chieffo A 
et al., 2009), and a pivotal mechanism is the loss of differentiation of SMCs that become 
able to proliferate and migrate (Owens GK et al., 2004). Interestingly, bindarit diminished 
the number of arterial PCNA-positive proliferating cells 7 days after stent implantation and 
monocyte/macrophage content in injured vessels at 28 days, clearly showing either 
antiproliferative and antiinflammatory activity. These effects were associated with a 
significant inhibition of MCP-1 plasma levels. The present results have some limitations. 
Although the porcine coronary model seems to represent the human coronary artery 
response to stenting, mimicking several clinical conditions, including thrombosis and 
neointimal formation (Touchard AG et al., 2006), it does not precisely simulate human in-
stent restenosis (Johnson GJ et al., Touchard AG et al., 2006). An important point in the 
present model is that stent implantation was performed in normal porcine coronary arteries, 
whereas in humans, much of the stent would be in contact with atheromatous plaque and not 
with media. Furthermore, in the present study the extent of in stent stenosis was examined 
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only at 28 days after stent implantation; for example, longer follow-up should be performed 
to assess the effect of bindarit on arterial healing. 
Bindarit also displayed antiproliferative effects in vitro, with significant inhibition of 
SMC proliferation and migration, effects associated with a significant and concentration-
related inhibition of MCP-1 amounts measured in the supernatants of stimulated cells treated 
with bindarit. In the arterial wall, SMCs normally exist in a quiescent, differentiated state, 
representing the contractile phenotype. During neointimal formation SMCs became 
activated and change towards the synthetic phenotype characterised by a high rate of 
proliferation and chemotactic response, changes in the cytoskeleton composition (Owens 
GK et al., 2004) and increased expression of extracellular matrix proteins, cytokines and 
chemokines (Owens GK et al., 2004; Charey DJ et al., 1991; Schober A, 2008). 
It is well known that chemokines mediate SMC activation during vascular injury 
(Schober A, 2008; Schober A et al., 2004), with MCP-1 (Selzman CH et al., 2002) and 
MCP-3 (Maddaluno M et al., 2012) shown to directly induce human SMC proliferation and 
MCP- 1 shown to induce cell migration (Parenti A et al., 2004) and the functional switch 
from the contractile to the synthetic phenotype (Denger S et al., 1999). This process is 
characterized by the downregulation of the differentiation markers such as α-SMA and 
calponin, concurrent with the upregulation of SMemb, that typifies immature SMCs (Owens 
GK et al., 2004). Importantly, it is now well established that differentiation and proliferation 
are not mutually exclusive and that many factors other than SMC proliferation status 
influence the differentiation state. Inhibition of proliferation alone is not sufficient to 
promote SMC differentiation (Alexander MR and Owens GK, 2012). However, anti 
proliferative agents used for inhibition of experimental neointimal formation, like 
simvastatin (Indolfi C et al., 2000), or human restenosis, like rapamycin (Martin KA et al. 
2007), are also able to induce SMC differentiated phenotype (Martin KA et al. 2007; Wada 
H et al., 2008). As above reported, bindarit is a selective inhibitor of MCP-1/CCL2, MCP-
3/CCL7, and MCP-2/CCL8 synthesis (Mirolo M et al., 2008) acting through the down-
regulation of NF-kB pathway (Mora E et al., 2012). To better understand the effect of 
bindarit on human SMC, we evaluated the phenotypic modulation of CASMC analyzing the 
contractile proteins (α-SMA, calponin and SMemb) expression. α-SMA is known to be 
expressed in a wide variety of non-vascular SMC cell types, under certain circumstances, for 
this reason we also analyzed calponin, that is univocally expressed by fully differentiated, 
mature SMC (Owens GK, 2004). We observed that the expression of contractile proteins in 
CASMCs changed in response to stimulation with FBS and the proinflammatory cytokine 
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TNF-α, with a reduction of α-SMA and calponin, and a concomitant increase of SMemb. 
These changes were significantly reversed by bindarit. CASMCs grown in presence of FBS 
exhibited a flattened morphology, feature of the synthetic phenotype. After bindarit 
treatment cells acquired the elongated and spindle-shaped morphology, typical feature of the 
contractile phenotype. Further bindarit inhibited CASMC proliferation, migration and 
invasion through the Matrigel barrier and reduced metalloproteinase (MMP)-9 activity, 
which is known to be key for VSMC migration into the intimal area (Newby AC et al., 
2000; Bendeck MP et al., 1994). Bindarit also reduced the levels of both MCP-1 and MCP-
3, data in line with results observed both in aortic rat and mice SMCs, as well as in pig 
coronary SMCs. 
The effect of bindarit on SMC phenotypic switching was confirmed in vivo in the rat 
carotid arteries subjected to balloon-induced endothelial denudation, an ideal experimental 
model for studying VSMC behavior (Selzman CH et al., 2002). The inhibition of neointimal 
formation observed in bindarit treated rats was associated with a modulation of the 
contractile proteins expression patterns. Indeed, treatment with bindarit reduced the 
expression of SMemb and increased the expression of α-SMA and calponin after vascular 
injury. These results demonstrates that bindarit regulates the contractile proteins expression 
and phenotype switching of SMCs, suggesting a novel underlying mechanisms by which 
bindarit can inhibit neointimal formation in human restenosis. 
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5. CONCLUSION 
 
The exploitation of the chemokine system as a drug target in vascular pathology has 
relied mainly on the development of receptor antagonists and blocking antibodies (Charo IF 
and Taubman MB, 2004). However, the attempt to block chemokines and their receptors in 
humans is more complex (Mirolo M et al., 2008). 
Here, we report the use of oral administration of bindarit as a viable approach to reduce 
neointimal hyperplasia in stent stenosis in pigs. Preclinical studies demonstrated that 
bindarit has a safe toxicological profile (rodent LD50 ≈2000 mg/kg PO and ≈600 mg/kg IP) 
and is devoid of immunosuppressive, mutagenic, and carcinogenic effects (Product Data 
Sheet, Angelini Research Center). Phase I clinical studies demonstrated that bindarit (up to a 
dose of 1200 mg BID) is well tolerated and confirmed the lack of overt toxicity suggested 
by preclinical studies (Product Data Sheet, Angelini Research Center). Results of Phase II 
clinical studies confirmed the good tolerability profile of bindarit and demonstrated, at 600 
mg BID, significant effects in kidney disease patients (Guglielmotti A et al., 2009; 
Ruggenenti P, 2009). 
Importantly, a double-blind, randomized, placebo-controlled phase II clinical trial (“The 
Effects of Bindarit in Preventing Stent Restenosis”, registered on ClinicaTrisl.gov, NCT 
01269242), with the aim of investigating the effect of bindarit in human coronary restenosis, 
showed that bindarit induced a significant reduction of in-stent late loss (Colombo A et al., 
2012). 
In conclusion, evidence of bindarit efficacy could provide clinicians with useful 
complementary or alternative therapeutic tools. 
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